US20030147922A1 - Vaccine against streptococcus pneumoniae capsular polysaccharides - Google Patents

Vaccine against streptococcus pneumoniae capsular polysaccharides Download PDF

Info

Publication number
US20030147922A1
US20030147922A1 US10/228,666 US22866602A US2003147922A1 US 20030147922 A1 US20030147922 A1 US 20030147922A1 US 22866602 A US22866602 A US 22866602A US 2003147922 A1 US2003147922 A1 US 2003147922A1
Authority
US
United States
Prior art keywords
polysaccharide
protein
mpl
streptococcus pneumoniae
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/228,666
Other languages
English (en)
Inventor
Carine Capiau
Marguerite Deschamps
Pierre Desmons
Craig Laferriere
Jan Poolman
Jean-Paul Prieels
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906437.0A external-priority patent/GB9906437D0/en
Priority claimed from GBGB9909077.1A external-priority patent/GB9909077D0/en
Priority claimed from GBGB9909466.6A external-priority patent/GB9909466D0/en
Priority claimed from GBGB9916677.9A external-priority patent/GB9916677D0/en
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Priority to US10/228,666 priority Critical patent/US20030147922A1/en
Publication of US20030147922A1 publication Critical patent/US20030147922A1/en
Priority to US11/240,193 priority patent/US20060093626A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Definitions

  • the present invention relates to bacterial polysaccharide antigen vaccines, their manufacture and the use of such polysaccharides in medicines.
  • A vaccines comprising a pneumococcal polysaccharide antigen, typically a pneumococcal polysaccharide conjugate antigen, formulated with a protein antigen from Streptococcus pneumoniae and optionally a Th1 inducing adjuvant;
  • B specific, advantageous pneumococcal polysaccharide conjugates adjuvanted with a Th1 adjuvant;
  • C bacteria polysaccharide conjugates in general conjugated to protein D from H. influenzae.
  • Streptococcus pneumoniae is a Gram-positive bacteria responsible for considerable morbidity and mortality (particularly in the young and aged), causing invasive diseases such as pneumonia, bacteremia and meningitis, and diseases associated with colonisation, such as acute Otitis media.
  • the rate of pneumococcal pneumonia in the U.S. for persons over 60 years of age is estimated to be 3 to 8 per 100,000. In 20% of cases this leads to bacteremia, and other manifestations such as meningitis, with a mortality rate close to 30% even with antibiotic treatment.
  • Pneumococcus is encapsulated with a chemically linked polysaccharide which confers serotype specificity.
  • a chemically linked polysaccharide which confers serotype specificity.
  • the capsule is the principle virulence determinant for pneumococci, as the capsule not only protects the inner surface of the bacteria from complement, but is itself poorly immunogenic.
  • Polysaccharides are T-independent antigens, and can not be processed or presented on MHC molecules to interact with T-cells. They can however, stimulate the immune system through an alternate mechanism which involves cross-linking of surface receptors on B cells.
  • Polysaccharide antigen based vaccines are well known in the art. Four that have been licensed for human use include the Vi polysaccharide of Salmonella typhi , the PRP polysaccharide from Haemophilus influenzae , the tetravalent meningococcal vaccine composed of serotypes A, C, W135 and Y, and the 23-Valent pneumococcal vaccine composed of the polysaccharides corresponding to serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33 (accounting for at least 90% of pneumococcal blood isolates).
  • the 23-valent unconjugated pneumococcal vaccine has shown a wide variation in clinical efficacy, from 0% to 81% (Fedson et al. (1994) Arch Intern Med. 154: 2531-2535). The efficacy appears to be related to the risk group that is being immunised, such as the elderly, Hodgkin's disease, splenectomy, sickle cell disease and agammaglobulinemics (Fine et al. (1994) Arch Intern Med. 154:2666-2677), and also to the disease manifestation.
  • the 23-valent vaccine does not demonstrate protection against pneumococcal pneumonia (in certain high risk groups such as the elderly) and otitis media diseases.
  • the present invention provides such an improved vaccine.
  • Aluminium-based adjuvants are examples of the carrier class of adjuvant which works through the “depot effect” it induces. Antigen is adsorbed onto its surface and when the composition is injected the adjuvant and antigen do not immediately dissipate in the blood stream—instead the composition persists in the local environment of the injection and a more pronounced immune response results.
  • carrier adjuvants have the additional known advantage of being suitable for stabilising antigens that are prone to breakdown, for instance some polysaccharide antigens.
  • 3D-MPL is an example of a non-carrier adjuvant. Its full name is 3-O-deacylated monophosphoryl lipid A (or 3 De-O-acylated monophosphoryl lipid A or 3-O-desacyl-4′ monophosphoryl lipid A) and is referred to as 3D-MPL to indicate that position 3 of the reducing end glucosamine is de-O-acylated. For its preparation, see GB 2220211 A. Chemically it is a mixture of 3-deacylated monophosphoryl lipid A with 4, 5 or 6 acylated chains. It was originally made in the early 1990's when the method to 3-O-deacylate the 4′-monophosphoryl derivative of lipid A (MPL) led to a molecule with further attenuated toxicity with no change in the immunostimulating activity.
  • MPL 4′-monophosphoryl derivative of lipid A
  • 3D-MPL has been used as an adjuvant either on its own or, preferentially, combined with a depot-type carrier adjuvant such as aluminium hydroxide, aluminium phosphate or oil-in-water emulsions.
  • a depot-type carrier adjuvant such as aluminium hydroxide, aluminium phosphate or oil-in-water emulsions.
  • antigen and 3D-MPL are contained in the same particulate structures, allowing for more efficient delivery of antigenic and immunostimulatory signals.
  • Studies have shown that 3D-MPL is able to further enhance the immunogenicity of an alum-adsorbed antigen [Thoelen et al. Vaccine (1998) 16:708-14; EP 689454-B1].
  • Such combinations are also preferred in the art for antigens that are prone to adsorption (for instance, bacterial polysaccharide conjugates), where adsorption onto alum tends to stabilise the antigen.
  • Precipitated aluminium-based adjuvants are mostly used as they are the only adjuvants that are currently used in licensed human vaccines. Accordingly, vaccines containing 3D-MPL in combination with aluminium-based adjuvants are favoured in the art due to their ease of development and speed of introduction onto the market.
  • MPL non 3-deacylated
  • MPL has been evaluated as an adjuvant with several monovalent polysaccharide-conjugate vaccine antigens.
  • Coinjection of MPL in saline enhanced the serum antibody response for four monovalent polysaccharide conjugates: pneumococcal PS 6B-tetanus toxoid, pneumococcal PS 12-diphtheria toxoid, and S. aureus type 5 and S. aureus type 8 conjugated to Pseudomonas aeruginosa exotoxin A [Schneerson et al. J. Immunology (1991) 147:2136-2140]. The enhanced responses were taught as being antigen-specific.
  • MPL in an oil-in-water emulsion consistently enhanced the effect of MPL in saline due to the presence of MPL and antigen in the same particulate structure, and was considered to be the adjuvant system of choice for optimal delivery of other polysaccharide conjugate vaccines.
  • Devi et al. [Infect. Immun. (1991) 59:3700-7] evaluated the adjuvant effect of MPL (non 3-deacylated) in saline on the murine antibody response to a TT conjugate of Cryptococcus neoformans capsular polysaccharide.
  • MPL non 3-deacylated
  • TT conjugate of Cryptococcus neoformans capsular polysaccharide.
  • the adjuvant effect of MPL with polysaccharides and polysaccharide-protein conjugates appears to be composition-dependent. Again, the incorporation of MPL in a suitable slow-release delivery systems (for instance using a carrier adjuvant) provides a more durable adjuvant effect and circumvents the problem of timing and delayed administration.
  • the present inventors have found that for certain pneumococcal polysaccharide conjugates, the immunogenicity of the vaccine composition is significantly greater when the antigen is formulated with 3D-MPL alone rather than with 3D-MPL in conjunction with a carrier adjuvant (such as an aluminium-based adjuvant). Furthermore the observed improvement is independent of the concentration of 3D-MPL used, and whether the particular conjugates are in a monovalent composition or whether they are combined to form a polyvalent composition.
  • polysaccharide antigen based vaccines are well known in the art.
  • the licensed polysaccharide vaccines mentioned above have different demonstrated clinical efficacy.
  • the Vi polysaccharide vaccine has been estimated to have an efficacy between 55% and 77% in preventing culture confirmed typhoid fever (Plotkin and Cam, (1995) Arch Intern Med 155: 2293-99).
  • the meningococcal C polysaccharide vaccine was shown to have an efficacy of 79% under epidemic conditions (De Wals P, et al. (1996) Bull World Health Organ. 74: 407-411).
  • the 23-valent pneumococcal vaccine has shown a wide variation in clinical efficacy, from 0% to 81% (Fedson et al. (1994) Arch Intern Med. 154: 2531-2535) As mentioned above, it is accepted that the protective efficacy of the pneumococcal vaccine is more or less related to the concentration of antibody induced upon vaccination.
  • Examples of these highly immunogenic carriers which are currently commonly used for the production of polysaccharide immunogens include the Diphtheria toxoid (DT or the CRM197 mutant), Tetanus toxoid (TT), Keyhole Limpet Haemocyanin (KLH), and the purified protein derivative of Tuberculin (PPD).
  • KLH is known as potent immunogen and has already been used as a carrier for IgE peptides in human clinical trials. However, some adverse reactions (DTH-like reactions or IgE sensitisation) as well as antibody responses against antibody have been observed.
  • the present invention provides a new carrier for use in the preparation of polysaccharide/polypeptide-based immunogenic conjugates, that does not suffer from the aforementioned disadvantages.
  • the present invention provides a protein D (EP 0 594 610 B1) from Haemophilus influenzae, or fragments thereof, as a carrier for polysaccharide based immunogenic compositions, including vaccines.
  • a protein D EP 0 594 610 B1
  • This carrier is particularly advantageous in combination vaccines.
  • the present invention provides a vaccine composition, comprising at least one Streptococcus pneumoniae polysaccharide antigen (preferably conjugated) and a Streptococcus pneumoniae protein antigen or immunologically functional equivalent thereof, optionally with a Th1 adjuvant (an adjuvant inducing a Th1 immune response).
  • a Th1 adjuvant an adjuvant inducing a Th1 immune response.
  • both a pneumococcal protein and Th1 adjuvant are included.
  • the compositions of the invention are particularly suited in the treatment of elderly pneumonia.
  • Pneumococcal polysaccharide vaccines may not be able to protect against pneumonia in the elderly population for which the incidence of this disease is very high.
  • the key defense mechanism against the pneumococcus is opsonophagocytosis (a humoral B-cell/neutrophil mediated event caused by the production of antibodies against the pneumococcal polysaccharide, the bacterium eventually becoming phagocytosed), however parts of the involved opsonic mechanisms are impaired in the elderly, i.e. superoxide production by PMN (polymorphonuclear cells), other reactive oxygen species production, mobilization of PMN, apoptosis of PMN, deformability of PMN.
  • Antibody responses may also be impaired in the elderly.
  • the present inventors have found that by simultaneously stimulating the cell mediated branch of the immune system (for instance T-cell meditated immunity) in addition to the humoral brach of the immune system (B-cell mediated), a synergy (or cooperation) results which is capable of enhancing the clearance of pneumococci from the host.
  • T-cell meditated immunity for instance T-cell meditated immunity
  • B-cell mediated humoral brach of the immune system
  • both arms of the immune system may synergise in this way if a pneumococcal polysaccharide (preferably conjugated) is administered with a pneumococcal protein (preferably a protein expressed on the surface of pneumococci, or secreted or released, which can be processed and presented in the context of Class II and MHC class I on the surface of infected mammalian cells).
  • a pneumococcal protein can trigger cell mediated immunity by itself
  • the inventors have also found that the presence of a Th1 inducing adjuvant in the vaccine formulation helps this arm of the immune system, and surprisingly further enhances the synergy between both arms of the immune system.
  • the present invention also provides an antigenic composition comprising one or more pneumococcal polysaccharide conjugates adjuvanted with 3D-MPL and substantially devoid of aluminium-based adjuvants, wherein at least one of the pneumococcal polysaccharide conjugates is significantly more immunogenic in compositions comprising 3D-MPL in comparison with compositions comprising 3D-MPL in conjunction with an aluminium-based adjuvant.
  • compositions comprising conjugates of one or more of the following pneumococcal capsular polysaccharides: serotype 4, 6B, 18C, 19F, and 23F.
  • each of the polysaccharides are surprisingly more immunogenic in compositions comprising 3D-MPL alone compared with compositions comprising 3D-MPL and an aluminium-based adjuvant.
  • a antigenic composition comprising the Streptococcus pneumoniae capsular polysaccharide serotype 4, 6B, 18C, 19F or 23F conjugated to an immunogenic protein and 3D-MPL adjuvant, wherein the composition is substantially devoid of aluminium-based adjuvants.
  • the present invention provides a combination antigenic composition substantially devoid of aluminium-based adjuvants and comprising 3D-MPL adjuvant and two or more pneumococcal polysaccharide conjugates chosen from the group consisting of: serotype 4; serotype 6B; serotype 18C; serotype 19F; and serotype 23F.
  • the present invention provides a polysaccharide conjugate antigen comprising a polysaccharide antigen derived from a pathogenic bacterium conjugated to protein D from Haemophilus influenzae or a protein D fragment thereof.
  • the invention provides polyvalent vaccine compositions where one or more of the polysaccharide antigens are conjugated to protein D.
  • the present invention provides an improved vaccine particularly for the prevention or amelioration of pnemococcal infection of the elderly (and/or infants and toddlers).
  • a patient is considered elderly if they are 55 years or over in age, typically over 60 years and more generally over 65 years.
  • a vaccine composition suitable for use in the elderly (and/or Infants and toddlers) comprising at least one Streptococcus pneumoniae polysaccharide antigen and at least one Streptococcus pneumoniae protein antigen.
  • the present invention provides a vaccine (suitable for the prevention of pneumonia in the elderly) comprising at least one Streptococcus pneumoniae polysaccharide antigen and at least one Streptococcus pneumoniae protein antigen and a Th1 adjuvant.
  • a vaccine composition comprising a pneumococcal polysaccharide antigen and a Th1 adjuvant.
  • the Streptococcus pneumoniae vaccine of the present invention will comprise polysaccharide antigens (preferably conjugated), wherein the polysaccharides are derived from at least four serotypes of pneumococcus.
  • the four serotypes include 6B, 14, 19F and 23F. More preferably, at least 7 serotypes are included in the composition, for example those derived from serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F.
  • At least II serotypes are included in the composition, for example the composition in one embodiment includes capsular polysaccharides derived from serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (preferably conjugated).
  • at least 13 polysaccharide antigens are included, although further polysaccharide antigens, for example 23 valent (such as serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F), are also contemplated by the invention.
  • serotypes 8 and 12F are advantageously included to form a 15 valent vaccine
  • serotypes 6A and 19A are advantageously included to form a 13 valent vaccine.
  • “immunologically functional equivalent” is defined as a peptide of protein comprising at least one protective epitope from the proteins of the invention. Such epitopes are characteristically surface-exposed, highly conserved, and can elicit an bactericidal antibody response in a host or prevent toxic effects.
  • the functional equivalent has at least 15 and preferably 30 or more contiguous amino acids from the protein of the invention.
  • fragments, deletions of the protein such as transmembrane deletion variants thereof (ie the use of the extracellular domain of the proteins), fusions, chemically or genetically detoxified derivatives and the like can be used with the proviso that they are capable of raising substantially the same immune response as the native protein.
  • Preferred proteins of the invention are those pneumococcal proteins which are exposed on the outer surface of the pneumococcus (capable of being recognised by a host's immune system during at least part of the life cycle of the pneumococcus), or are proteins which are secreted or released by the pneumococcus.
  • the protein is a toxin, adhesin, 2-component signal tranducer, or lipoprotein of Streptococcus pneumoniae , or immunologically functional equivalents thereof.
  • Particularly preferred proteins to be included in such a combination vaccine include but are not limited to: pneumolysin (preferably detoxified by chemical treatment or mutation) [Mitchell et al. Nucleic Acids Res. Jul. 11, 1990; 18(13): 4010 “Comparison of pneumolysin genes and proteins from Streptococcus pneumoniae types 1 and 2.”, Mitchell et al. Biochim Biophys Acta Jan. 23, 1989; 1007(1): 67-72 “Expression of the pneumolysin gene in Escherichia coli : rapid purification and biological properties.”, WO 96/05859 (A.
  • the proteins used in the present invention are preferably selected from the group pneumolysin, PsaA, PspA, PspC, CbpA or a combination of two or more such proteins.
  • the present invention also encompasses immunologically functional equivalents of such proteins (as defined above).
  • the protein can help to induce a T-cell mediated response against pneumococcal disease—particularly required for protection against pneumonia—which cooperates with the humoral branch of the immune system to inhibit invasion by pneumococci, and to stimulate opsonophagocytosis.
  • a Streptococcus pneumoniae vaccine comprising a pneumococcus polysaccharide conjugate vaccine comprising polysaccharide antigens derived from at least four serotypes, preferably at least seven serotypes, more preferably at least eleven serotypes, and at least one, but preferably two, Streptococcus pneumoniae proteins.
  • one of the proteins is Pneumolysin or PsaA or PspA or CbpA (most preferably detoxified pneumolysin).
  • a preferred combination contains at least pneumolysin or a derivative thereof and PspA.
  • polysaccharides per se are poor immunogens.
  • polysaccharides may be conjugated to protein carriers, which provide bystander T-cell help. It is preferred, therefore, that the polysaccharides utilised in the invention are linked to such a protein carrier.
  • examples of such carriers which are currently commonly used for the production of polysaccharide immunogens include the Diphtheria and Tetanus toxoids (DT, DT CRM197 and TT respectively), Keyhole Limpet Haemocyanin (KLH), OMPC from N. meningitidis , and the purified protein derivative of Tuberculin (PPD).
  • the present invention provides in a preferred embodiment a new carrier for use in the preparation of polysaccharide-based immunogen constructs, that does not suffer from these disadvantages.
  • the preferred carrier for the pneumococcal polysaccharide based immunogenic compositions (or vaccines) is protein D from Haemophilus influenzae (EP 594610-B), or fragments thereof. Fragments suitable for use include fragments encompassing T-helper epitopes. In particular a protein D fragment will preferably contain the N-terminal 1 ⁇ 3 of the protein.
  • a further preferred carrier for the pneumococcal polysaccharide is the pneumococcal protein itself (as defined above in section “Pneumococcal Proteins of the invention”).
  • the vaccines of the present invention are preferably adjuvanted.
  • Suitable adjuvants include an aluminium salt such as aluminium hydroxide gel (alum) or aluminium phosphate, but may also be a salt of calcium, iron or zinc, or may be an insoluble suspension of acylated tyrosine, or acylated sugars, cationically or anionically derivatised polysaccharides, or polyphosphazenes.
  • the adjuvant be selected to be a preferential inducer of a TH1 type of response to aid the cell mediated branch of the immune response.
  • Th1-type cytokines tend to favour the induction of cell mediated immune responses to a given antigen, whilst high levels of Th2-type cytokines tend to favour the induction of humoral immune responses to the antigen.
  • Th1 and Th2-type immune response are not absolute. In reality an individual will support an immune response which is described as being predominantly Th1 or predominantly Th2.
  • TH1 and TH2 cells different patterns of lymphokine secretion lead to different functional properties. Annual Review of Immunology, 7, p145-173).
  • Th1-type responses are associated with the production of the INF- ⁇ and IL-2 cytokines by T-lymphocytes.
  • Th1-type immune responses are not produced by T-cells, such as IL-12.
  • Th2-type responses are associated with the secretion of IL4, IL-5, IL-6, IL-10.
  • Suitable adjuvant systems which promote a predominantly Th1 response include, Monophosphoryl lipid A or a derivative thereof, particularly 3-de-O-acylated monophosphoryl lipid A, and a combination of monophosphoryl lipid A, preferably 3-de-O-acylated monophosphoryl lipid A (3D-MPL) together with an aluminium salt.
  • An enhanced system involves the combination of a monophosphoryl lipid A and a saponin derivative, particularly the combination of QS21 and 3D-MPL as disclosed in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol as disclosed in WO 96/33739.
  • a particularly potent adjuvant formulation involving QS21, 3D-MPL and tocopherol in an oil in water emulsion is described in WO 95/17210, and is a preferred formulation.
  • the vaccine additionally comprises a saponin, more preferably QS21.
  • the formulation may also comprises an oil in water emulsion and tocopherol (WO 95/17210).
  • the present invention also provides a method for producing a vaccine formulation comprising mixing a protein of the present invention together with a pharmaceutically acceptable excipient, such as 3D-MPL.
  • Unmethylated CpG containing oligonucleotides (WO 96/02555) are also preferential inducers of a Th1 response and are suitable for use in the present invention.
  • compositions of the invention comprise one or more conjugated pneumococcal polysaccharides, one or more pneumococcal proteins and a Th1 adjuvant.
  • the induction of a cell mediated response by way of a pneumococcal protein (as described above) and the cooperation between both arms of the immuen system may be aided using such a Th-1 adjuvant, resulting in a particularly effective vaccine against pneumococcal disease in general, and, importantly, against pneumococcal pneumonia in the elderly.
  • an immunogen or vaccine as herein described for use in medicine.
  • a composition comprising a pneumococcal polysaccharide conjugate and a Th1 adjuvant (preferably 3D-MPL) which is capable of seroconverting or inducing a humoral antibody response against the polysaccharide antigen within a population of non-responders.
  • a pneumococcal polysaccharide conjugate and a Th1 adjuvant (preferably 3D-MPL) which is capable of seroconverting or inducing a humoral antibody response against the polysaccharide antigen within a population of non-responders.
  • a Th1 adjuvant preferably 3D-MPL
  • the present inventors have found that a combination of a conjugated pneumococcal polysaccharide (which is prone to low response in a particular population) with a Th1 adjuvant (see “Th1 adjuvants of the invention” above) can surprisingly overcome this non-responsiveness.
  • a conjugated pneumococcal polysaccharide which is prone to low response in a particular population
  • Th1 adjuvants of the invention see “Th1 adjuvants of the invention” above
  • 3D-MPL should be used, and most preferably 3D-MPL devoid of aluminium-based adjuvant (which provides a better response still).
  • the present invention thus provides such compositions, and further provides a method of treating non-responders to pneumococcal polysaccharides by administering such compositions, and still further provides a use of a Th1 adjuvant in the manufacture of a medicament comprising conjugated pneumococcal polysaccharide antigens, in the treatment against (or protection from) pneumococcal disease in individuals which are non-responsive to the polysaccharide antigen.
  • a method of preventing or ameliorating pneumonia in an elderly human comprising administering a safe and effective amount of a vaccine, as described herein, comprising a Streptococcus pneumoniae polysaccharide antigen and either a Th1 adjuvant, or a pneumococcal protein (and preferably both), to said elderly patient.
  • a vaccine as described herein, comprising a Streptococcus pneumoniae polysaccharide antigen and either a Th1 adjuvant, or a pneumococcal protein (and preferably both), to said elderly patient.
  • a method of preventing or ameliorating otitis media in Infants or toddlers comprising administering a safe and effective amount of a vaccine comprising a Streptococcus pneumoniae polysaccharide antigen and either a Streptococcus pneumoniae protein antigen or a Th1 adjuvant (and preferably both), to said Infant or toddler.
  • polysaccharide antigen is present as a polysaccharide protein conjugate.
  • the vaccine preparations of the present invention may be used to protect or treat a mammal susceptible to infection, by means of administering said vaccine via systemic or mucosal route.
  • administrations may include injection via the intramuscular, intraperitoneal, intradermal or subcutaneous routes; or via mucosal administration to the oral/alimentary, respiratory, genitourinary tracts.
  • Intranasal administration of vaccines for the treatment of pneumonia or otitis media is preferred (as nasopharyngeal carriage of pneumococci can be more effectively prevented, thus attenuating infection at its earliest stage).
  • the amount of conjugate antigen in each vaccine dose is selected as an amount which induces an immunoprotective response without significant, adverse side effects in typical vaccines. Such amount will vary depending upon which specific immunogen is employed and how it is presented. Generally, it is expected that each dose will comprise 0.1-100 ⁇ g of polysaccharide, preferably 0.1-50 ⁇ g, preferably 0.1-10 ⁇ g, of which 1 to 5 ⁇ g is the most preferable range.
  • the content of protein antigens in the vaccine will typically be in the range 1-100 ⁇ g, preferably 5-50 ⁇ g, most typically in the range 5-25 ⁇ g.
  • Optimal amounts of components for a particular vaccine can be ascertained by standard studies involving observation of appropriate immune responses in subjects. Following an initial vaccination, subjects may receive one or several booster immunisations adequately spaced.
  • Vaccine preparation is generally described in Vaccine Design (“The subunit and adjuvant approach” (eds Powell M. F. & Newman M. J.) (1995) Plenum Press New York). Encapsulation within liposomes is described by Fullerton, U.S. Pat. No. 4,235,877.
  • the term “pneumococcal polysaccharide conjugates of the invention” describes those conjugates of Streptococcus pneumoniae capsular polysaccharides which are more immunogenic in compositions comprising 3D-MPL in comparison with compositions comprising 3D-MPL in conjunction with an aluminium-based adjuvant (for example, conjugates of serotype 4; serotype 6B; serotype 18C; serotype 19F; or serotype 23F).
  • the term “substantially devoid of aluminium-based adjuvants” describes a composition which does not contain sufficient aluminium-based adjuvant (for example aluminium hydroxide, and, particularly, aluminium phosphate) to cause any decrease in the immunogenicity of a pneumococcal polysaccharide conjugate of the invention in comparison to an equivalent composition comprising 3D-MPL with no added aluminium-based adjuvant.
  • the antigenic composition should contain adjuvant that consists essentially of 3D-MPL.
  • Quantitities of aluminium-based adjuvant added per dose should preferably be less than 50 ⁇ g, more preferably less than 30 ⁇ g, still more preferably less than 10 ⁇ g, and most preferably there is no aluminium-based adjuvant added to the antigenic compositions of the invention.
  • the determination of whether a pneumococcal polysaccharide conjugate is significantly more immunogenic in compositions comprising 3D-MPL in comparison with compositions comprising 3D-MPL in conjunction with an aluminium-based adjuvant should be established as described in Example 2.
  • the ratio of GMC IgG concentration (as determined in Example 2) between compositions comprising 3D-MPL alone versus an equivalent composition comprising 3D-MPL in conjunction with aluminium phosphate adjuvant should be more than 2, preferably more than 5, more preferably more than 7, still more preferably more than 9, and most preferably more than 14.
  • Examples of such carriers which may be used include the Diphtheria, Diphtheria mutant, and Tetanus toxoids (DT, CRM197 and TT respectively), Keyhole Limpet Haemocyanin (KLH), the purified protein derivative of Tuberculin (PPD), and OMPC of Neisseria meningitidis.
  • KLH Keyhole Limpet Haemocyanin
  • PPD purified protein derivative of Tuberculin
  • OMPC of Neisseria meningitidis.
  • protein D from Haemophilus influenzae (EP 0 594 610-B), or fragments thereof (see section C) is used as the immunogenic protein carrier for the pneumococcal polysaccharides of the invention.
  • the antigenic composition of the invention comprises pneumococcal polysaccharide serotype (PS) 4 conjugated to an immunogenic protein and formulated with 3D-MPL adjuvant, where the composition is substantially devoid of aluminium-based adjuvant.
  • the antigenic composition comprises PS 6B, 18C, 19F, or 23F, respectively, conjugated to an immunogenic protein and formulated with 3D-MPL adjuvant, where the composition is substantially devoid of aluminium-based adjuvant.
  • a combination antigenic composition comprising two or more pneumococcal polysaccharide conjugates from the group PS 4, PS 6B, PS 18C, PS19F, and PS 23F formulated with 3D-MPL adjuvant, where the composition is substantially devoid of aluminium-based adjuvant.
  • a preferred aspect of the invention provides a combination antigenic composition comprising one or more pneumococcal polysaccharide conjugates of the invention in combination with one or more further pneumococcal polysaccharide conjugates, where the composition is formulated with 3D-MPL adjuvant, but is substantially devoid of aluminium-based adjuvant.
  • combination antigenic compositions which contain at least one and preferably 2, 3, 4 or all 5 of the PS 4, 6B, 18C, 19F, or 23F pneumococcal polysaccharide conjugates, and in addition any combination of other pneumococcal polysaccharide conjugates, which are formulated with 3D-MPL adjuvant but substantially devoid of aluminium-based adjuvant.
  • the Streptococcus pneumoniae combination antigenic composition of the present invention will comprise polysaccharide conjugate antigens, wherein the polysaccharides are derived from at least four, seven, eleven, thirteen, fifteen or twenty-three serotypes (see “ Streptococcus pneumoniae Polysaccharide Antigens of the Invention” above for preferred combinations of serotypes depending on the disease to be treated).
  • the antigenic compositions of the invention are preferably used as vaccine compositions to prevent (or treat) pneumococcal infections, particularly in the elderly and infants and toddlers.
  • Further embodiments of the present invention include: the provision of the above antigenic compositions for use in medicine; a method of inducing an immune response to a Streptococcus pneumoniae capsular polysaccharide conjugate, comprising the steps of administering a safe and effective amount of one of the above antigenic compositions to a patient; and the use of one of the above antigenic compositions in the manufacture of a medicament for the prevention (or treatment) of pneumococcal disease.
  • the antigenic compositions (and vaccines) hereinbefore described are lyophilised up until they are about to be used, at which point they are extemporaneously reconstituted with diluent. More preferably they are lyophilsed in the presence of 3D-MPL, and are extemporaneously reconstituted with saline solution.
  • Lyophilising the compositions results in a more stable composition (for instance it prevents the breakdown of the polysaccharide antigens).
  • the process is also surprisingly responsible for a higher antibody titre still against the pneumococcal polysaccharides. This has been shown to be particularly significant for PS 6B conjugates.
  • Another aspect of the invention is thus a lyophilised antigenic composition comprising a PS 6B conjugate adjuvanted with 3D-MPL and substantially devoid of aluminium-based adjuvants.
  • the present invention provides a protein D from Haemophilus influenzae , or fragments thereof, as a carrier for polysaccharide based immunogenic composition, including vaccines. Fragments suitable for use include fragments encompassing T-helper epitopes. In particular protein D fragment will preferably contain the N-terminal 1 ⁇ 3 of the protein.
  • Protein D is an IgD-binding protein from Haemophilus influenzae (EP 0 594 610 B1) and is a potential immunogen.
  • Polysaccharides to be conjugated to Protein D contemplated by the present invention include, but are not limited to the Vi polysaccharide antigen against Salmonella typhi , meningococcal polysaccharides (including type A, C, W135 and Y, and the polysaccharide and modified polysaccharides of group B meningococcus), polysaccharides from Staphylococcus aureus, polysaccharides from Streptococcus agalactae , polysaccharides from Streptococcus pneumoniae, polysaccharides from Mycobacterium e.g.
  • Mycobacterium tuberculosis (such as mannophosphoinisitides trehaloses, mycolic acid, mannose capped arabinomannans, the capsule therefrom and arabinogalactans), polysaccharide from Cryptococcus neoformans , the lipopolysaccharides of non-typeable Haemophilus influenzae , the capsular polysaccharide from Haemophilus influenzae b, the lipopolysaccharides of Moraxella catharralis , the lipopolysaccharides of Shigella sonnei , the lipopeptidophosphoglycan (LPPG) of Trypanosoma cruzi , the cancer associated gangliosides GD3, GD2, the tumor associated mucins, especially the T-F antigen, and the sialyl T-F antigen, and the HIV associated polysaccharide that is structurally related to the T-F antigen.
  • mannophosphoinisitides trehalose
  • the polysaccharide may be linked to the carrier protein by any known method (for example, by Likhite, U.S. Pat. No. 4,372,945 and by Armor et al., U.S. Pat. No. 4,474,757).
  • CDAP conjugation is carried out (WO 95/08348).
  • the cyanylating reagent 1-cyano-dimethylaminopyridinium tetrafluoroborate (CDAP) is preferably used for the synthesis of polysaccharide-protein conjugates.
  • the cyanilation reaction can be performed under relatively mild conditions, which avoids hydrolysis of the alkaline sensitive polysaccharides. This synthesis allows direct coupling to a carrier protein.
  • the polysaccharide is solubilized in water or a saline solution.
  • CDAP is dissolved in acetonitrile and added immediately to the polysaccharide solution.
  • the CDAP reacts with the hydroxyl groups of the polysaccharide to form a cyanate ester.
  • the carrier protein is added. Amino groups of lysine react with the activated polysaccharide to form an isourea covalent link.
  • the invention provides a method of producing polysaccharide protein D conjugates comprising the steps of activating the polysaccharide and linking the polysaccharide to the protein D.
  • an immunogenic composition (or vaccine) formulation for the prevention of Streptococcus pneumoniae infections.
  • the Streptococcus pneumoniae vaccine of the present invention will comprise protein D polysaccharide conjugates, wherein the polysaccharide is derived from at least four, seven, eleven, thirteen, fifteen or 23 serotypes. See above “ Streptococcus pneumoniae Polysaccharide Antigens of the Invention” for preferred combinations of serotypes depending on the disease to be treated.
  • Neisseria meningitidis vaccine in particular from serotypes A, B, C W-135 and Y.
  • Neisseria meningitidis is one of the most important causes of bacterial meningitis.
  • the carbohydrate capsule of these organisms can act as a virulence determinant and a target for protective antibody. Carbohydrates are nevertheless well known to be poor immunogens in young children.
  • the present invention provides a particularly suitable protein carrier for these polysaccharides, protein D, which provides T-cell epitopes that can activate a T-cell response to aid polysaccharide antigen specific B-cell proliferation and maturation, as well as the induction of an immunological memory.
  • the present invention also contemplates combination vaccines which provide protection against a range of different pathogens.
  • a protein D carrier is surprisingly useful as a carrier in combination vaccines where multiple polysaccharide antigens are conjugated.
  • epitope suppression is likely to occur if the same carrier is used for each polysaccharide.
  • WO 98/51339 presented compositions to try to minimise this interference by conjugating a proportion of the polysaccharides in the composition onto DT and the rest onto TT.
  • protein D is particularly suitable for minimising such epitopic suppression effects in combination vaccines.
  • One or more polysaccharides in a combination may be advantageously conjugated onto protein D, and preferably all antigens are conjugated onto protein D within such combination vaccines.
  • a preferred combination includes a vaccine that affords protection against Neisseria meningitidis C and Y (and preferably A) infection wherein the polysaccharide antigen from one or more of serotypes Y and C (and most preferably A) are linked to protein D.
  • Haemophilus influenzae polysaccharide based vaccine (PRP conjugated with preferably TT, DT or CRM197, or most preferably with protein D) may be formulated with the above combination vaccines.
  • the vaccines of the invention can be formulated with, or administered separately, but at the same time with the well known ‘trivalent’ combination vaccine comprising Diphtheria toxoid (DT), tetanus toxoid (TT), and pertussis components [typically detoxified Pertussis toxoid (PT) and filamentous haemagglutinin (FHA) with optional pertactin (PRN) and/or agglutinin 1+2], for example the marketed vaccine INFANRIX-DTPaTM (SmithKlineBeecham Biologicals) which contains DT, TT, PT, FHA and PRN antigens, or with a whole cell pertussis component for example as marketed by SmithKlineBeecham Biologicals s.a
  • the combined vaccine may also comprise other antigen, such as Hepatitis B surface antigen (HBsAg), Polio virus antigens (for instance inactivated trivalent polio virus—IPV), Moraxella catarrhalis outer membrane proteins, non-typeable Haemophilus influenzae proteins, N.meningitidis B outer membrane proteins.
  • HsAg Hepatitis B surface antigen
  • Polio virus antigens for instance inactivated trivalent polio virus—IPV
  • Moraxella catarrhalis outer membrane proteins non-typeable Haemophilus influenzae proteins
  • N.meningitidis B outer membrane proteins such as HBsAg
  • Polio virus antigens for instance inactivated trivalent polio virus—IPV
  • Moraxella catarrhalis outer membrane proteins such as non-typeable Haemophilus influenzae proteins, N.meningitidis B outer membrane proteins.
  • Examples of preferred Moraxella catarrhalis protein antigens which can be included in a combination vaccine are: OMP106 [WO 97/41731 (Antex) & WO 96/34960 (PMC)]; OMP21; LbpA & LbpB [WO 98/55606 (PMC)]; ThpA & TbpB [WO 97/13785 & WO 97/32980 (PMC)]; CopB [Helminen M E, et al. (1993) Infect. Immun. 61:2003-2010]; UspA1/2 [WO 93/03761 (University of Texas)]; and OmpCD.
  • non-typeable Haemophilus influenzae antigens which can be included in a combination vaccine (especially for the prevention of otitis media) include: Fimbrin protein [(U.S. Pat. No. 5,766,608—Ohio State Research Foundation)] and fusions comprising peptides therefrom [eg LB1(f) peptide fusions; U.S. Pat. No. 5,843,464 (OSU) or WO 99/64067]; OMP26 [WO 97/01638 (Cortecs)]; P6 [EP 281673 (State University of New York)]; TbpA and TbpB; Hia; Hmw1,2; Hap; and D15.
  • Fimbrin protein (U.S. Pat. No. 5,766,608—Ohio State Research Foundation)] and fusions comprising peptides therefrom [eg LB1(f) peptide fusions; U.S. Pat. No. 5,843,464 (OSU)
  • Preferred Peadiatric vaccines contemplated by the present invention are:
  • N. meningitidis C polysaccharide conjugate and Haemophilus influenzae b polysaccharide conjugate optionally with N. meningitidis A and/or Y polysaccharide conjugate, provided that at least one polysaccharide antigen, and preferably all are conjugated to protein D.
  • the present invention provides an immunogenic composition comprising a Streptococcus pneumoniae polysaccharide—protein D conjugate and a Streptococcus pneumoniae protein antigen.
  • the polysaccharide—protein D conjugate antigens of the present invention are preferably adjuvanted in the vaccine formulation of the invention.
  • Suitable adjuvants include an aluminium salt such as aluminum hydroxide gel (alum) or aluminium phosphate, but may also be a salt of calcium, iron or zinc, or may be an insoluble suspension of acylated tyrosine, or acylated sugars, cationically or anionically derivatised polysaccharides, or polyphosphazenes.
  • the adjuvant be selected to be a preferential inducer of a Th1 type of response.
  • Th1 adjuvants see “Th1 adjuvants of the invention” above.
  • an immunogen or vaccine as herein described for use in medicine.
  • Protein D is also advantageously used in a vaccine against otitis media, as it is in itself an immunogen capable of producing B-cell mediated protection against non-typeable H. influenzae (ntHi). ntHi may invade host cells, and evade the B-cell mediated effects induced by the protein antigen.
  • the present inventors have surprisingly found a way of increasing the effectiveness of protein D (either by itself or as a carrier for a polysaccharide) as an antigen for an otitis media vaccine. This is done by adjuvanting the protein D such that a strong Th1 response is induced in the subject such that the cell mediated arm of the immune system is optimised against protein D.
  • a lyophilised composition comprising protein D and a Th1 adjuvant (preferably 3D-MPL) which is reconstituted shortly before administration.
  • the invention thus also provides such compositions, a process for making such compositions (by lyophilising a mixture comprising protein D and a Th1 adjuvant), and a use of such a composition in the treatment of otitis media.
  • Th1 adjuvants of the invention preferably 3D-MPL
  • the present invention is therefore applicable to any immunogen to which a stronger Th1 immune response is required.
  • immunogens comprise bacterial, viral and tumour protein antigens, as well as self proteins and peptides.
  • the 11-valent candidate vaccine includes the capsular polysaccharides serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F which were made essentially as described in EP 72513. Each polysaccharide is activated and derivatised using CDAP chemistry (WO 95/08348) and conjugated to the protein carrier. All the polysaccharides are conjugated in their native form, except for the serotype 3 (which was size-reduced to decrease its viscosity).
  • Protein Carrier [0151]
  • the protein carrier selected is the recombinant protein D (PD) from Non typeable Haemophilus influenzae , expressed in E. coli.
  • PD recombinant protein D
  • Protein D is highly conserved among H. influenzae of all serotypes and non-typeable strains.
  • the vector pHIC348 containing the DNA sequence encoding the entire protein D gene has been obtained from Dr. A. Forsgren, Department of Medical Microbiology, University of Lund, Malmö General Hospital, Malmö, Sweden.
  • the DNA sequence of protein D has been published by Janson et al. (1991) Infect. Immun. 59: 119-125.
  • the expression vector pMG1 is a derivative of pBR322 (Gross et al., 1985) in which bacteriophage ⁇ derived control elements for transcription and translation of foreign inserted genes were introduced (Shatzman et al., 1983). In addition, the Ampicillin resistance gene was exchanged with the Kanamycin resistance gene.
  • the E. coli strain AR58 was generated by transduction of N99 with a P1 phage stock previously grown on an SA500 derivative (galE::TN10, lambdaKil ⁇ cI857 ⁇ H1).
  • N99 and SA500 are E. coli K12 strains derived from Dr. Martin Rosenberg's laboratory at the National Institute of Health.
  • the DNA encoding the protein has been cloned into the expression vector pMG 1.
  • This plasmid utilises signals from lambdaphage DNA to drive the transcription and translation of inserted foreign genes.
  • the vector contains the promoter PL, operator OL and two utilisation sites (NutL and NutR) to relieve transcriptional polarity effects when N protein is provided (Gross et al., 1985).
  • Vectors containing the PL promoter are introduced into an E. coli lysogenic host to stabilise the plasmid DNA. Lysogenic host strains contain replication-defective lambdaphage DNA integrated into the genome (Shatzman et al., 1983).
  • the chromosomal lambdaphage DNA directs the synthesis of the cI repressor protein which binds to the OL repressor of the vector and prevents binding of RNA polymerase to the PL promoter and thereby transcription of the inserted gene.
  • the cI gene of the expression strain ARS8 contains a temperature sensitive mutant so that PL directed transcription can be regulated by temperature shift, i.e. an increase in culture temperature inactivates the repressor and synthesis of the foreign protein is initiated. This expression system allows controlled synthesis of foreign proteins especially of those that may be toxic to the cell (Shimataka & Rosenberg, 1981).
  • the AR58 lysogenic E. coli strain used for the production of the protein D carrier is a derivative of the standard NIH E. coli K12 strain N99 (F ⁇ su ⁇ galK2, lacZ ⁇ thr ⁇ ). It contains a defective lysogenic lambdaphage (galE::TN10, lambdaKil ⁇ cI857 ⁇ H1). The Kil ⁇ phenotype prevents the shut off of host macromolecular synthesis. The cI857 mutation confers a temperature sensitive lesion to the cI repressor. The ⁇ H1 deletion removes the lambdaphage right operon and the hosts bio, uvr3, and ch1A loci.
  • the AR58 strain was generated by transduction of N99 with a P1 phage stock previously grown on an SA500 derivative (galE::TN10, lambdaKil ⁇ cI857 ⁇ H1).
  • the introduction of the defective lysogen into N99 was selected with tetracycline by virtue of the presence of a TN10 transposon coding for tetracyclin resistance in the adjacent galE gene.
  • the pMG 1 vector which contains the gene encoding the non-structural S1 protein of Influenzae virus (pMGNSI) was used to construct pMGMDPPrD.
  • the protein D gene was amplified by PCR from the pHIC348 vector (Janson et al. 1991) with PCR primers containing NcoI and XbaI restriction sites at the 5′ and 3′ ends, respectively.
  • the NcoI/XbaI fragment was then introduced into pMGNS1 between NcoI and XbaI thus creating a fusion protein containing the N-terminal 81 amino acids of the NS1 protein followed by the PD protein.
  • This vector was labeled pMGNS1PrD.
  • the protein D does not contain a leader peptide or the N-terminal cysteine to which lipid chains are normally attached. The protein is therefore neither excreted into the periplasm nor lipidated and remains in the cytoplasm in a soluble form.
  • the final construct pMG-MDPPrD was introduced into the AR58 host strain by heat shock at 37° C. Plasmid containing bacteria were selected in the presence of Kanamycin. Presence of the protein D encoding DNA insert was demonstrated by digestion of isolated plasmid DNA with selected endonucleases.
  • the recombinant E. coli strain is referred to as ECD4.
  • Expression of protein D is under the control of the lambda P L promoter/ O L Operator.
  • the host strain AR58 contains a temperature-sensitive cI gene in the genome which blocks expression from lambda P L at low temperature by binding to O L . Once the temperature is elevated cI is released from O L and protein D is expressed. At the end of the fermentation the cells are concentrated and frozen.
  • the extraction from harvested cells and the purification of protein D was performed as follows.
  • the cell culture homogenate is clarified by centrifugation and cell debris are removed by filtration.
  • the filtered lysate is applied to a cation exchange chromatography column (SP Sepharose Fast Flow).
  • SP Sepharose Fast Flow SP Sepharose Fast Flow
  • impurities are retained on an anionic exchange matrix (Q Sepharose Fast Flow).
  • PD does not bind onto the gel and can be collected in the flow through.
  • the protein D containing ultrafiltration retentate is finally passed through a 0.2 ⁇ m membrane.
  • the activation and coupling conditions are specific for each polysaccharide. These are given in Table 1. Native polysaccharide (except for PS3) was dissolved in NaCl 2M or in water for injection. The optimal polysaccharide concentration was evaluated for all the serotypes.
  • CDAP CDAP/PS ratio 0.75 mg/mg PS
  • 0.2M triethylamine was added to obtain the specific activation pH.
  • the activation of the polysaccharide was performed at this pH during 2 minutes at 25° C.
  • Protein D (the quantity depends on the initial PS/PD ratio) was added to the activated polysaccharide and the coupling reaction was performed at the specific pH for 1 hour. The reaction was then quenched with glycine for 30 minutes at 25° C. and overnight at 4° C.
  • conjugates were purified by gel filtration using a Sephacryl 500HR gel filtration column equilibrated with 0.2M NaCl.
  • the carbohydrate and protein content of the eluted fractions was determined.
  • the conjugates were pooled and sterile filtered on a 0.22 ⁇ m sterilizing membrane.
  • the PS/Protein ratios in the conjugate preparations were determined.
  • the level of “free” residual protein D was determined by using a method with SDS treatment of the sample.
  • the conjugate was heated 10 min at 100° C. in presence of SDS 0.1% and injected on a SEC-HPLC gel filtration column (TSK 3000-PWXL).
  • SEC-HPLC gel filtration column TSK 3000-PWXL
  • the molecular size was performed on a SEC-HPLC gel filtration column (TSK 5000-PWXL).
  • the protein conjugates can be adsorbed onto aluminium phosphate and pooled to form the final vaccine.
  • the rats were immunised with an 11 valent pneumococcal conjugate vaccine comprising the following polysaccharide serotypes conjugated onto protein D: 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F.
  • the concentrated, adsorbed monovalents were prepared according to the following procedure. 50 ⁇ g AlPO 4 (pH 5.1) was mixed with 5 ⁇ g conjugated polysaccharides for 2 hours. The pH was adjusted to pH 5.1 and the mixture was left for a further 16 hours. 1500 mM NaCl was added to make up the salt concentration to 150 mM. After 5 minutes 5 mg/mL 2-phenoxyethanol was added. After a further 30 minutes the pH was adjusted to 6.1, and left for more than 3 days at 4° C.
  • the eleven concentrated, adsorbed PS-PD monovalents were mixed at the correct ratio.
  • the complement of AlPO 4 was added as the diluent A.
  • 3D-MPL was added either as an aqueous solution (non adsorbed, Way 1 see below) or as the diluent B or C (3D-MPL adsorbed on AlPO 4 at 2 doses, Way 2, see below).
  • 3D-MPL was added to the combined adsorbed conjugates as an aqueous suspension. It was mixed to the undecavalent for 10 minutes at room temperature and stored at 4° C. until administration.
  • 3D-MPL was preadsorbed onto AlPO 4 before addition to the combined adsorbed conjugates (diluent B and C).
  • diluent B and C combined adsorbed conjugates
  • 1 ml of diluent an aqueous suspension of 3D-MPL (250 or 561 ⁇ g) was mixed with 1 mg of AlPO 4 in NaCl 150 mM pH 6.3 for 5 min at room temperature. This solution was diluted in NaCl pH 6.1/phenoxy and incubated overnight at 4 ° C.
  • the ELISA was performed to measure rat IgG using the protocol derived from the WHO Workshop on the ELISA procedure for the quantitation of IgG antibody against Streptococcus pneumoniae capsular polysaccharides in human serum. In essence, purified capsular polysaccharide is coated directly on the microtitre plate. Serum samples are pre-incubated with the cell-wall polysaccharide common to all pneumococcus (substance C) and which is present in ca. 0.5% in pneumococcal polysaccharides purified according to disclosure (EP 72513 B1). Jackson ImmunoLaboratories Inc. reagents were employed to detect bound murine IgG. The titration curves were referenced to internal standards (monoclonal antibodies) modeled by logistic log equation. The calculations were performed using SoftMax Pro software. The maximum absolute error on these results expected to be within a factor of 2. The relative error is less than 30%.
  • Opsonic titres were determined for serotypes 3, 6B, 7F, 14, 19F and 23F using the CDC protocol ( Streptococcus pneumoniae Opsonophagocytosis using Differentiated HL60 cells, version 1.1) with purified human PMN and baby rabbit complement. Modification included the use of in-house pneumococcal strains, and the phagocytic HL60 cells were replaced by purified human neutrophils PMN (there is a high degree of correlation between these phagocytic cells). In addition, 3 mm glass beads were added to the microtitre wells to increase mixing, and this allowed reduction of the phagocyte:bacteria ratio which was recommended to be 400.
  • Table 11 shows that when 3D-MPL and 3D-MPL/AlPO 4 compositions are compared (comparing the process of formulation, and the dose of 3D-MPL), 5 of the polysaccharide conjugates are significantly improved, in terms of immunogenicity, when formulated with just 3D-MPL rather than 3D-MPL plus AlPO 4 : PS 4, PS 6B, PS 18C, PS 19F, and PS 23F.
  • peroxydase-conjugated goat anti-mouse IgG (Jackson) diluted 5000 ⁇ in PBS/ Tween-20 0.05% were incubated (100 ⁇ l/well) for 30 minutes at 20° C. under agitation. After washing, plates were incubated for 15 min at room temperature with 100 ⁇ l/well of revelation buffer (OPDA 0.4 mg/ml and H 2 O 2 0.05% in 100 mM pH 4.5 citrate buffer). Revelation was stopped by adding 50 ⁇ l/well HCl 1N. Optical densities were read at 490 and 620 nm by using Emax immunoreader (Molecular Devices). Antibody titre were calculated by the 4 parameter mathematical method using SoftMaxPro software.
  • This assay was done for measuring the ability of serum antibodies to inhibit the pneumolysin (PLY) hemolytic activity.
  • serum samples were treated 2 ⁇ as follows: they were mixed with 1 equal volume of chloroform and then incubated for 45 minutes under agitation. Supernatants were collected after centrifugation for 10 minutes at 1000 rpm. Cholesterol-cleared sera were diluted (serial 2-fold dilutions in 1 mM dithiothreitol. 0.01% BSA, 15 mM TRIS, 150 mM NaCl, pH 7.5) in 96 well microplates (Nunc).
  • Recombinant native pneumolysin was dialyzed against Phosphate 50 mM NaCl 500 mM pH 7.6 buffer. All following steps were done at 39.5° C. under episodic agitation.
  • Tween-80 10% (1/250 v/v), N-acetyl tryptophan 57.4 mM pH 7.6 (3/100 v/v), glycin 2.2 M in Phosphate buffer (1/100 v/v) and formaldehyde 10% in Phosphate buffer (3/100 v/v) were added into PLY solution.
  • formaldehyde 10% was added again, at 3/100 and 2/100 v/v ratio, respectively.
  • FIGS. 1A and 1B show ELISA IgG and HemoLysis Inhibition titers (HLI) measured in post-III sera.
  • compositions containing pneumolysin it may be preferable to use chemically detoxified pneumolysin rather than mutationally detoxified pneumolysin. This is because detoxified mutants obtained to date still have residual toxin activity—chemically detoxifed pneumolysin does not. It is therefore considered another aspect of the invention that, in general, compositions comprising pneumolysin (or pneumolysin mutants) that has been chemically detoxified for use in a vaccine, should be adjuvanted with a Th1 adjuvant, preferably 3D-MPL. Such compositions are provided by the invention.
  • a method of increasing the immune response of chemically-detoxifed pneumolysin within an immunogenic composition comprising the steps of adding a Th1 adjuvant (preferably 3D-MPL) to the composition, is also envisaged.
  • Groups of 12 female 4 week-old OF1 mice were immunized subcutaneously at days 0 and 14 with formulations containing A: 50 ⁇ g AlPO4; B: 0.1 ⁇ g PS/serotype of PD-conjugated 11-valent polysaccharide vaccine+50 ⁇ g AlPO4; or C: 0.1 ⁇ g PS/serotype of PD-conjugated 11-valent polysaccharide vaccine+10 ⁇ g PdB (provided by J. Paton, Children's Hospital, North Sydney, Australia)+50 ⁇ g AlPO4+5 ⁇ g 3D-MPL (supplied by Ribi Immunochem). Challenge was done at day 21 as described above.
  • Antibody titers were then compared to bacteria colony numbers measured in lungs of the corresponding animals collected at 6 hours post-challenge. R 2 were calculated on Log/Log linear regressions.
  • Vaccine Groups Four groups of 16 mice were passively immunised (i.p.) on day ⁇ 1 with 100 ⁇ l of undiluted rat anti-polysaccharide antisera according to the groups detailed below. (total 64 mice) IgG Concentration in Group Specificity Antisera G1 ⁇ -PS-6B 5 ⁇ g/ml. G2 ⁇ -PS-6B 2 ⁇ g/ml. G3 ⁇ -PS-6B 0.75 ⁇ g/ml. G4 Control 0 ⁇ g/ml.
  • Organism S. pneumoniae N1387 (serotype 6) was harvested from trypticase soy agar plates (TSA) supplemented with 5% horse blood and suspended in 6 ml of PBS. Immediately prior to infection, 1 ml bacterial suspension was diluted into 9 ml of cooled molten nutrient agar (BBL) and kept at 41° C. Mice received approx 6.0 log10 cfu/mouse in a volume 50 ul.
  • TSA trypticase soy agar plates
  • BBL cooled molten nutrient agar
  • mice were anesthetized as described above and infected with S. pneumoniae N1387 (50 ⁇ l cooled bacterial suspension) by intra-bronchial instillation via non-surgical intra-tracheal intubation. This method was described by Woodnut and Berry (Antimicrob. Ag. Chemotherap. 43: 29 (1999)).
  • mice/group On day 3 post infection, 8 mice/group were sacrificed by CO2 overdose and lungs were excised and homogenized in 1 ml PBS. Tenfold serial dilutions were prepared in PBS to enumerate viable bacterial numbers. Samples were inoculated (20 ⁇ l) in triplicate onto TSA plates supplemented with 5% horse blood and incubated overnight at 37° C. prior to evaluation. Further sets of mice were sacrificed on day 7 and sampled as above.
  • Animals 128 male CD-1 mice (6 weeks old at old at immunisation, 10 weeks old at infection) from Charles River, St. Constant, Quebec. Canada. Animals weighed approx 20 gm at 6 weeks and 38 g at 10 weeks.
  • PdB/AlPO4 (10/50) 100 ⁇ l i.p. ⁇ -PS 1-4 100 ⁇ l s.c.
  • PdB/MPL/AlPO4 100 ⁇ l i.p. ⁇ -PS (10/5/50) 1-5 100 ⁇ l s.c.
  • MPL/AlPO4 5/50
  • 100 ⁇ l i.p. ⁇ -PS 1-6 100 ⁇ l s.c. MPL/AlPO4 (5/50) None
  • mice were anesthetized (3% isoflurane plus 1 L/min O2).
  • Bacterial inocula were prepared by harvesting growth of S. pneumoniae N1387 (serotype 6) from trypticase soy agar plates (TSA) supplemented with 5% horse blood and suspending in 6 ml of PBS.
  • a ten-fold dilution (1 ml plus 9 ml) was prepared in cooled molten nutrient agar (kept at 41° C.) immediately prior to infection.
  • Mice were infected by intra-bronchial instillation via intra-tracheal intubation and received approximately 6.0 log10 cfu/mouse in a volume of 50 ⁇ l. This method was described by Woodnut and Berry (Antimicrob. Ag. Chemotherap. 43: 29 (1999)).
  • the outcome measure for comparison of treatment was the number of bacteria in the lungs at 3 and 7 day post infection. Results are presented as group means with standard deviations. Statistical analysis was performed using the Students t-test where a P value of ⁇ 0.05 was considered significant.
  • Bacterial numbers in all groups were approx 2 logs lower at 8 days than at 3 days. indicating that the infection was resolving.
  • group 1-4 had all three elements, PdB, 3D-MPL and passively administered anti-polysaccharide antibody. This conclusion is supported by the mortality rate. Group 1-4 had only 2/8 deaths compared to 5/10 for groups 1-5 and 1-3.
  • mice were immunised intramuscularly. Injections of the groups listed in the following table were performed on days 0 and 21. Test bleeds were obtained on day 35, (14 days after the second dose). TABLE Immunisation Schedule for 1-year-old Balb/c mice immunised with clinical lots of pneumococcal-polysaccharide Protein D conjugate vaccine.
  • mice 1 Pneumovax-23 Buffer 20 2.5 mcg 2a 11-valent Pn-PD Buffer 20 0.1 mcg 2b 11-valent Pn-PD 11-valent Pn-PD 20 0.1 mcg 0.1 mcg 3a 11-valent Pn-PD + MPL Buffer 20 0.1 mcg + 5 mcg 3b 11-valent Pn-PD + MPL 11-valent Pn-PD + MPL 20 0.1 mcg + 5 mcg 0.
  • the sera were tested by ELISA for IgG antibodies to the pneumococcal polysaccharides following the CDC/WHO consensus protocol, that is, after neutralisation of the sera with cell-wall polysaccharide.
  • the ELISA was calibrated to give antibody concentrations in mcg/ml using serotype specific IgG1 monoclonal antibodies.
  • Group 1 shows the effect of immunisation with plain polysaccharides, which normally induce only IgM in animals. Most IgG levels are below the threshold of detection; nevertheless, balb/c mice were able to make IgG to a few pneumococcal polysaccharides, notably serotypes 3, 19F and 14.
  • a dosage-dependent response (group 4 vs group 2) was observed only for serotypes 7F and 19F, but these observations were not statistically significant.
  • a greater response was observed after two doses (b groups vs a groups) for serotypes 3, 6B, 7F and 19F, and PD, and these observations were statistically significant in many cases with all 3 formulations.
  • mice used in the experiment were non-responsive to PS 23 (plain or conjugated). Interestingly although antibody levels against the polysaccharide remained low regardless of the vaccine composition used, many more mice responded to PS 23 when 3D-MPL was used as the adjuvant (the seroconversion being significantly higher).
  • Th1 adjuvants particularly 3D-MPL
  • a method of relieving non-responsiveness with the aforementioned composition using the two dose administration scheme described above is yet another aspect.
  • the source of group C polysaccharide is the strain C11 of N. meningitidis . This is fermented using classical fermentation techniques (EP 72513).
  • the dry powder polysaccharides used in the conjugation process are identical to Mencevax (SB Biologicals s.a.).
  • the surface growth is then re-suspended in sterilized fermentation medium and inoculated with this suspension on one Roux bottle containing Mueller Hinton medium supplemented with yeast extract dialysate (10%, v/v) and sterile glass beads. After incubation of the Roux bottle during 23 to 25 hrs at 36° C. in a water saturated air incubator, the surface growth is re-suspended in 10 ml sterile fermentation medium and 0.2 to 0.3 ml of this suspension are inoculated onto 12 other Mueller Hinton medium Roux bottles.
  • This suspension is then aseptically transferred into the fermenter using sterile syringes.
  • the fermentation of meningococcus is performed in fermenters contained in a clean room under negative pressure.
  • the fermentation is generally completed after 10-12 hrs corresponding to approximately 10 10 bacteria/ml (i.e. the early stationary phase) and detected by pH increase.
  • the entire broth is heat inactivated (12 min at 56° C.) before centrifugation. Before and after inactivation, a sample of the broth is taken and streaked onto Mueller Hinton medium petri dishes.
  • the purification process is a multi-step procedure performed on the entire fermentation broth.
  • the inactivated culture is clarified by centrifugation and the supernatant is recovered.
  • CTAB Cetyltrimethylammonium Bromide/CTAB, CETAVLON R
  • CTAB forms insoluble complexes with polyanions such as polysaccharides, nucleic acid and proteins depending on their pI. Following ionic controlled conditions, this method can be used to precipitate impurities (low conductivity) or polysaccharides (high conductivity).
  • the polysaccharides included in clarified supernatant are precipitated using a diatomaceous earth (CELITE R 545) as matrix to avoid formation of insoluble inert mass during the different precipitations/purifications.
  • CELITE R 545 diatomaceous earth
  • Step 1 PSC-CTAB complex fixation on CELITE R 545 and removal of cells debris, nucleic acids and proteins by washing with CTAB 0.05%.
  • Step 2 Elution of PS with EtOH 50%. The first fractions which are turbid and contain impurities and LPS are discarded. The presence of PS in the following fractions is verified by floculation test.
  • Step 3 PS-CTAB complex re-fixation on CELITE R 545 and removal of smaller nucleic acids and proteins by CTAB 0.05% washing.
  • Step 4 Elution of PS with EtOH 50%. The first turbid fractions are discarded. The presence of PS in the following fractions is verified by floculation test.
  • the eluate is filtered and the filtrate containing crude polysaccharide collected.
  • the polysaccharide is precipitated from the filtrate by adding ethanol to a final concentration of 80%.
  • the polysaccharide is then recovered as a white powder, vaccum dried and stored at ⁇ 20° C.
  • CDAP conjugation technology was preferred to the classical CNBr activation and coupling via a spacer to the carrier protein.
  • the polysaccharide is first activated by cyanylation with 1-cyano-4-dimethylamino-pyridinium tetrafluoroborate (CDAP).
  • CDAP is a water soluble cyanylating reagent in which the electrophilicity of the cyano group is increased over that of CNBr, permitting the cyanylation reaction to be performed under relatively mild conditions.
  • the polysaccharide can be directly coupled to the carrier protein through its amino groups without introducing any spacer molecule.
  • the unreacted estercyanate groups are quenched by means of extensive reaction with glycine.
  • the total number of steps involved in the preparation of conjugate vaccines is reduced and most importantly potentially immunogenic spacer molecules are not present in the final product.
  • Activation of polysaccharides with CDAP introduces a cyanate group in the polysaccharides and dimethylaminopyridine (DMAP) is liberated.
  • DMAP dimethylaminopyridine
  • the cyanate group reacts with NH2-groups in the protein during the subsequent coupling procedure and is converted to a carbamate.
  • CDAP solution 100 mg/ml freshly prepared in acetonitrile is added to reach a CDAP/PS (w/w) ratio of 0.75.
  • the PS-PD conjugate is purified in a cold room by gel permeation chromatography on a S400HR Sephacryl gel to remove small molecules (including DMAP) and unconjugated PD: Elution—NaCl 150 mM pH 6.5: Monitoring—UV 280 nm, pH and conductivity.
  • PS-PD conjugates are eluted first followed by free PD and finally DMAP.
  • DMAP Downlinking Agent
  • Fractions containing conjugate as detected by DMAB (PS) and ⁇ BCA (protein) are pooled.
  • the pooled fractions are sterile filtered (0.2 ⁇ m)
  • AlPO4 is washed with NaCl 150 mM and centrifuged (4 ⁇ );
  • the pellet is then resuspended in NaCl 150 mM then filtrated (100 ⁇ m);
  • the filtrate is heat sterilized.
  • This washed AlPO 4 is referred to as WAP (washed autoclaved phosphate).
  • the PSC-PD conjugate bulk is adsorbed on AlPO4 WAP before the final formulation of the finished product.
  • AlPO 4 WAP was stirred with PSC-PD for 5 minutes at room temperature. The pH was adjusted to 5.1, and the mixture was stirred for a further 18 hours at room temperature. NaCl solution was added to 150 mM, and the mixture was stirred for 5 minutes at room temperature. 2-phenoxyethanol was added to 5 mg/mL and the mixture was stirred for 15 minutes at room temperature, then adjusted to pH 6.1.
  • mice were bled on days 14 (14 Post I), 28 (14 Post II) and 42 (28 Post II).
  • Geometric mean concentrations (GMCs) of polysaccharide C specific antibodies measured by ELISA were expressed in ⁇ g IgG/ml using purified IgG as reference.
  • Bactericidal antibodies were measured on pooled sera and titres expressed as the reciprocal of the dilution able to kill 50% of bacteria, using the N. meningitidis C11 strain in presence of baby rabbit complement.
  • the dose-response obtained shows a plateau from the 2.5 ⁇ g dose.
  • Results indicate that there is a good booster response between 14 Post I and 14 Post II.
  • Antibody levels at 28 Post II are at least equivalent to those at 14 Post II.
  • Bactericidal antibody titres are concordant with ELISA concentrations and confirm the immunogenicity of the PSC-PD conjugate.
  • PSC-PD conjugate induces an anamnestic response demonstrating that PSC, when conjugated, becomes a T cell dependent antigen.
  • Anti-PSC antibody concentrations measured by ELISA correlate well with bactericidal antibody titres showing that antibodies induced by the PSC-PD conjugate are functional against N. meningitidis serogroup C.
  • the CDAP chemistry appears to be a suitable method for making immunogenic PSC-PD conjugates.
  • a dry powder of polysaccharide A is dissolved for one hour in NaCl 0.2 M solution to a final concentration of 8 mg/ml. pH is then fixed to a value of 6 with either HCl or NaOH and the solution is thermoregulated at 25° C. 0.75 mg CDAP/mg PSA (a preparation to 100 mg/ml acetonitrile) is added to the PSA solution. After 1.5 minutes without pH regulation, NaOH 0.2 M is added to obtain a pH of 10. 2.5 minutes later, protein D (concentrated to 5 mg/ml) is added according to a PD/PSA ratio of approximately 1. A pH of 10 is maintained during the coupling reaction period of 1 hour.
  • PSA polysaccharide A
  • mice were used as animal model to test the immunogenicity of the conjugates.
  • the conjugates were adsorbed either onto AlPO 4 or Al(OH) 3 (10 ⁇ g of PS onto 500 ⁇ g of Al 3+ ) or not adsorbed.
  • the mice were injected as followed: 2 injections at two week intervals (2 ⁇ g PS/injection).
  • the formulation is also important. AlPO 4 appears to be the most appropriate adjuvant in this model.
  • the conjugates induce a boost effect which is not observed when polysaccharides are injected alone.
  • Conjugates of N. meningitidis A and C were obtained with a final PS/protein ratio of 1 and 0.6-0.7 (w/w) respectively. Free PS and free carrier protein were below 10% and 15% respectively. Polysaccharide recovery is higher than 70%. Conjugates of PSA and PSC obtainable by the above improved (optimised) CDAP process (regardless of the carrier protein, but preferably protein D) is thus a further aspect of the invention.
  • H. influenzae b is one of the major causes of meningitis in children under 2 years old.
  • the capsular polysaccharide of H. influenzae (PRP) as a conjugate onto tetanus toxoid is well known (conjugated by chemistry developed by J. Robbins).
  • CDAP is an improved chemistry. The following is account of optimal CDAP conditions found for conjugating PRP, preferably to PD.
  • the 3 most critical parameters to optimise the quality of the end product are: the initial ratio of polysaccharide/protein; the initial concentration of polysaccharide; and the coupling pH.
  • a reaction cube was thus designed with the above 3 conditions as the three axes.
  • the ratio of the final ratio PS/protein with respect to the initial ratio is a measure of the efficiency of coupling.
  • pH does not effect the ratio of ratios.
  • the initial ratio does (1.75 at low initial ratio, 1.26 at high initial ratios).
  • the final ratio depends on the initial ratio and the [PS]. The most sizeable final ratios are obtained with a combination high initial ratios and high [PS]. The effect of pH on the final ratio is not as significant as a weak [PS].
  • Protein D as an Antigen How Its Protective Efficacy Against Non-typeable H. influenzae Can Be Improved by Formulating It with 3D-MPL
  • mice Female Balb/c Mice (10 per group) were immunized (intramuscularly) with the eleven valent pneumococcal polysaccharide-protein D conjugate vaccine for a first time at the age of 20 weeks (D0) and received a second immunization two weeks later (D14). Blood was collected 7 days after the second immunization. Antibody titres against protein D were measured in terms of the quantity of IgG1, IgG2a and IgG2b type antibodies.
  • Freeze-dried undecavalent vaccines (without AlPO 4 ) were prepared by combining the conjugates with 15.75% lactose, stirring for 15 minutes at room temperature, adjusting the pH to 6.1 ⁇ 0.1, and lyophilising (the cycle usually starting at ⁇ 69° C., gradually adjusting to ⁇ 24° C. over 3 hours, then retaining this temperature for 18 hours, then gradually adjusting to ⁇ 16° C. over 1 hour, then retaining this temperature for 6 hours, then gradually adjusting to +34° C. over 3 hours, and finally retaining this temperature over 9 hours).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
US10/228,666 1999-03-19 2002-08-26 Vaccine against streptococcus pneumoniae capsular polysaccharides Abandoned US20030147922A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/228,666 US20030147922A1 (en) 1999-03-19 2002-08-26 Vaccine against streptococcus pneumoniae capsular polysaccharides
US11/240,193 US20060093626A1 (en) 1999-03-19 2005-09-30 Vaccine

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GB9906437.0 1999-03-19
GBGB9906437.0A GB9906437D0 (en) 1999-03-19 1999-03-19 Vaccine
GB9909077.1 1999-04-20
GBGB9909077.1A GB9909077D0 (en) 1999-04-20 1999-04-20 Novel compositions
GB9909466.6 1999-04-23
GBGB9909466.6A GB9909466D0 (en) 1999-04-23 1999-04-23 Vaccines
GBGB9916677.9A GB9916677D0 (en) 1999-07-15 1999-07-15 Vaccine
GB9916677.9 1999-07-15
US93693301A 2001-12-19 2001-12-19
US10/228,666 US20030147922A1 (en) 1999-03-19 2002-08-26 Vaccine against streptococcus pneumoniae capsular polysaccharides

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
PCT/EP2000/002465 Continuation WO2000056358A2 (en) 1999-03-19 2000-03-17 Vaccine against streptococcus pneumoniae capsular polysaccharides
US93693301A Continuation 1999-03-19 2001-12-19
US09936933 Continuation 2001-12-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/240,193 Continuation US20060093626A1 (en) 1999-03-19 2005-09-30 Vaccine

Publications (1)

Publication Number Publication Date
US20030147922A1 true US20030147922A1 (en) 2003-08-07

Family

ID=27451884

Family Applications (8)

Application Number Title Priority Date Filing Date
US10/228,666 Abandoned US20030147922A1 (en) 1999-03-19 2002-08-26 Vaccine against streptococcus pneumoniae capsular polysaccharides
US10/929,042 Pending US20050031646A1 (en) 1999-03-19 2004-08-27 Vaccine
US11/216,226 Abandoned US20060002961A1 (en) 1999-03-19 2005-08-31 Vaccine
US11/240,193 Abandoned US20060093626A1 (en) 1999-03-19 2005-09-30 Vaccine
US12/612,988 Expired - Lifetime US8926985B2 (en) 1999-03-19 2009-11-05 Vaccine
US12/793,408 Abandoned US20100291138A1 (en) 1999-03-19 2010-06-03 Vaccine
US12/973,899 Abandoned US20110217329A1 (en) 1999-03-19 2010-12-21 Vaccine
US14/550,345 Expired - Fee Related US9168313B2 (en) 1999-03-19 2014-11-21 Vaccine

Family Applications After (7)

Application Number Title Priority Date Filing Date
US10/929,042 Pending US20050031646A1 (en) 1999-03-19 2004-08-27 Vaccine
US11/216,226 Abandoned US20060002961A1 (en) 1999-03-19 2005-08-31 Vaccine
US11/240,193 Abandoned US20060093626A1 (en) 1999-03-19 2005-09-30 Vaccine
US12/612,988 Expired - Lifetime US8926985B2 (en) 1999-03-19 2009-11-05 Vaccine
US12/793,408 Abandoned US20100291138A1 (en) 1999-03-19 2010-06-03 Vaccine
US12/973,899 Abandoned US20110217329A1 (en) 1999-03-19 2010-12-21 Vaccine
US14/550,345 Expired - Fee Related US9168313B2 (en) 1999-03-19 2014-11-21 Vaccine

Country Status (32)

Country Link
US (8) US20030147922A1 (uk)
EP (6) EP1776962A1 (uk)
JP (4) JP2002540074A (uk)
KR (3) KR20020000785A (uk)
CN (3) CN1192798C (uk)
AR (3) AR022964A1 (uk)
AT (3) ATE459373T1 (uk)
AU (3) AU750913B2 (uk)
BE (1) BE1025464I2 (uk)
BR (4) BR0009163A (uk)
CA (3) CA2366314C (uk)
CY (3) CY1107561T1 (uk)
CZ (3) CZ303653B6 (uk)
DE (4) DE60038166T2 (uk)
DK (2) DK1163000T3 (uk)
ES (3) ES2300255T3 (uk)
FR (1) FR10C0008I2 (uk)
HK (3) HK1043728B (uk)
HU (4) HUP0200664A2 (uk)
IL (5) IL145045A0 (uk)
LU (1) LU91652I2 (uk)
MX (1) MXPA01009452A (uk)
MY (2) MY125202A (uk)
NL (1) NL300415I1 (uk)
NO (4) NO20014322L (uk)
NZ (3) NZ513841A (uk)
PL (3) PL203917B1 (uk)
PT (2) PT1163000E (uk)
SI (2) SI1162999T1 (uk)
TR (3) TR200102739T2 (uk)
TW (3) TWI286938B (uk)
WO (3) WO2000056358A2 (uk)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060051378A1 (en) * 2002-05-14 2006-03-09 Guidice Giuseppe D Mucosal vaccines with chitosan adjuvant and meningococcal antigens
US20060147466A1 (en) * 2002-05-14 2006-07-06 Chiron Srl Mucosal combination vaccines for bacterial meningitis
US20060228380A1 (en) * 2005-04-08 2006-10-12 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070116714A1 (en) * 1995-06-07 2007-05-24 Smithkline Beecham Biologicals Sa Vaccine Comprising a Polysaccharide Antigen-Carrier Protein Conjugate and Free Carrier Protein
US20070184071A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070207090A1 (en) * 2002-05-14 2007-09-06 Novartis Vaccines And Diagnostics, Inc. Mucosal meningococcal vaccines
WO2007071710A3 (en) * 2005-12-22 2007-11-29 Glaxosmithkline Biolog Sa Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
US20100209450A1 (en) * 2007-06-26 2010-08-19 Ralph Leon Biemans Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
US20100316666A1 (en) * 2005-04-08 2010-12-16 Wyeth Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition
US20110071279A1 (en) * 2005-04-08 2011-03-24 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US20110206692A1 (en) * 2006-06-09 2011-08-25 Novartis Ag Conformers of bacterial adhesins
WO2013191459A1 (ko) * 2012-06-20 2013-12-27 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
US8808707B1 (en) * 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
WO2015095868A1 (en) * 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
RU2595845C2 (ru) * 2003-10-02 2016-08-27 Новартис Вэксинес Энд Дайэгностикс С.Р.Л. Жидкие вакцины для множественных серогрупп менингококков
WO2017220753A1 (en) 2016-06-22 2017-12-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
US9981029B2 (en) * 2012-12-11 2018-05-29 Sk Chemical Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2018169303A1 (ko) * 2017-03-15 2018-09-20 주식회사 엘지화학 다가 폐렴구균 백신 조성물
US10105431B2 (en) * 2014-01-21 2018-10-23 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
US10688170B2 (en) 2017-06-10 2020-06-23 Inventprise, Llc Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
US10772918B2 (en) 2013-05-10 2020-09-15 California Institute Of Technology Probiotic prevention and treatment of colon cancer
US11116828B2 (en) 2017-12-06 2021-09-14 Merck Sharp & Dohme Corp. Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
US11419887B2 (en) 2010-04-07 2022-08-23 California Institute Of Technology Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
US11622973B2 (en) 2007-11-09 2023-04-11 California Institute Of Technology Immunomodulating compounds and related compositions and methods
US11642406B2 (en) 2018-12-19 2023-05-09 Merck Sharp & Dohme Llc Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof

Families Citing this family (241)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7078042B2 (en) * 1995-09-15 2006-07-18 Uab Research Foundation Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
ES2283012T3 (es) 1996-01-04 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Bacterioferritina de helicobacter pylori.
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US20010016200A1 (en) * 1998-04-23 2001-08-23 Briles David E. Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
DE69932717T2 (de) 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa Methoden und produkte zur induzierung mukosaler immunität
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
CZ303653B6 (cs) 1999-03-19 2013-01-30 Smithkline Beecham Biologicals S. A. Imunogenní prostredek
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
MXPA03003690A (es) 2000-10-27 2004-05-05 Chiron Spa Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
EA006947B1 (ru) 2001-01-23 2006-06-30 Авентис Пастер Поливалентная менингококковая полисахаридно-белковая конъюгированная вакцина
PT1361890E (pt) 2001-02-23 2011-06-07 Glaxosmithkline Biolog Sa Formulações vacinais de influenza para distribuição intradérmica
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0109297D0 (en) * 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
ES2312649T3 (es) 2001-12-12 2009-03-01 Novartis Vaccines And Diagnostics S.R.L. Inmunizacion frente a chlamydia trachomatis.
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
US7501134B2 (en) 2002-02-20 2009-03-10 Novartis Vaccines And Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
WO2004032958A1 (en) 2002-10-11 2004-04-22 Chiron Srl Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
JP5116971B2 (ja) * 2002-10-15 2013-01-09 インターセル アーゲー Ｂ群連鎖球菌の接着因子をコードする核酸、ｂ群連鎖球菌の接着因子、およびその使用
ES2649048T3 (es) 2002-11-01 2018-01-09 Glaxosmithkline Biologicals S.A. Procedimiento de secado
CA2501077C (en) 2002-11-12 2016-06-21 Gerald B. Pier Polysaccharide vaccine for staphylococcal infections
EP2279746B1 (en) 2002-11-15 2013-10-02 Novartis Vaccines and Diagnostics S.r.l. Surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
AU2003300919A1 (en) 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
JP2006520746A (ja) 2002-12-27 2006-09-14 カイロン コーポレイション リン脂質を含む免疫原性組成物
FR2850106B1 (fr) * 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
WO2004067030A2 (en) * 2003-01-30 2004-08-12 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
AU2004220590B2 (en) * 2003-03-07 2010-02-18 Inhibitex, Inc. Polysaccharide - Staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US8084235B2 (en) * 2003-03-13 2011-12-27 Glaxosmithkline Biologicals S.A. Purification process for bacterial cytolysin
CA2520124A1 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of benzazole compounds for immunopotentiation
PL1631264T5 (pl) 2003-06-02 2018-09-28 Glaxosmithkline Biologicals Sa Kompozycje immunogenne oparte na biodegradowalnych mikrocząstkach zawierających toksoid błonicy i tężca
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
BRPI0510315A (pt) 2004-04-30 2007-10-16 Chiron Srl integração de vacinação com conjugado meningocócico
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
US7444197B2 (en) * 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
WO2006002422A2 (en) 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
EP2612679A1 (en) 2004-07-29 2013-07-10 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
NZ555937A (en) 2005-01-27 2009-05-31 Childrens Hosp & Res Ct Oak GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
SI2351772T1 (sl) 2005-02-18 2016-11-30 Glaxosmithkline Biologicals Sa Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso
CN101203529A (zh) 2005-02-18 2008-06-18 诺华疫苗和诊断公司 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
WO2006113528A2 (en) 2005-04-18 2006-10-26 Novartis Vaccines And Diagnostics Inc. Expressing hepatitis b virus surface antigen for vaccine preparation
KR101408113B1 (ko) 2005-06-27 2014-06-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
BRPI0615420A2 (pt) 2005-09-01 2011-05-17 Novartis Vaccines & Diagnostic vacinação múltipla que inclui meningococo do sorogrupo c
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
BRPI0707154B8 (pt) * 2006-01-17 2022-12-20 Forsgren Arne composição de vacina
CN101024079B (zh) * 2006-02-17 2012-02-01 福州昌晖生物工程有限公司 肺炎链球菌多糖-外膜蛋白结合疫苗及制备方法
KR101411425B1 (ko) * 2006-03-17 2014-06-24 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 복합 다가 면역원성 콘쥬게이트의 제조 방법
NZ572054A (en) 2006-03-22 2011-12-22 Novartis Ag Regimens for immunisation with meningococcal conjugates
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
JO3418B1 (ar) * 2006-03-30 2019-10-20 Glaxosmithkline Biologicals Sa عملية اقتران خاصة ب pnag وبروتين حامل
EP2476434A1 (en) * 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogenic composition
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
JP2010500399A (ja) 2006-08-16 2010-01-07 ノバルティス アーゲー 尿路病原性大腸菌由来の免疫原
CL2007002909A1 (es) * 2006-10-10 2008-04-18 Wyeth Corp Metodo para reduccion o extraccion de impurezas de proteinas a partir de lisado celular de streptoccocus pneumoniae que comprende calentar dicho lisado, separar a los precipitantes a partir de dicho lisado produciendo un lisado que contiene polisacar
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
KR101621837B1 (ko) 2007-09-12 2016-05-17 노파르티스 아게 Ｇａｓ57 돌연변이 항원 및 ｇａｓ57 항체
JP5701058B2 (ja) 2007-10-19 2015-04-15 ノバルティス アーゲー 髄膜炎菌ワクチン処方物
AU2008335457B2 (en) 2007-12-07 2015-04-16 Glaxosmithkline Biologicals S.A. Compositions for inducing immune responses
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CN104292312A (zh) 2007-12-21 2015-01-21 诺华股份有限公司 链球菌溶血素o的突变形式
WO2009094730A1 (en) * 2008-02-01 2009-08-06 Newcastle Innovation Limited Vaccine compositions
NZ587382A (en) 2008-02-21 2012-01-12 Novartis Ag Meningococcal fhbp polypeptides
EP2631245A1 (en) 2008-03-10 2013-08-28 Children's Hospital & Research Center at Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
RU2532911C2 (ru) 2008-07-21 2014-11-20 Дзе Брихэм Энд Уимен'З Хоспитал, Инк. Способы и композиции, относящиеся к синтетическим бета-1,6-глюкозаминолигосахаридам
ES2586308T3 (es) 2008-10-27 2016-10-13 Glaxosmithkline Biologicals Sa Procedimiento de purificación de un hidrato de carbono de Streptococcus del grupo A
EP2865389A1 (en) 2008-12-09 2015-04-29 Pfizer Vaccines LLC IgE CH3 peptide vaccine
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
US8585505B2 (en) 2008-12-15 2013-11-19 Tetris Online, Inc. Inter-game interactive hybrid asynchronous computer game infrastructure
AU2009329193A1 (en) 2008-12-17 2011-07-14 Novartis Ag Meningococcal vaccines including hemoglobin receptor
AU2010203223B9 (en) 2009-01-05 2015-10-08 Epitogenesis Inc. Adjuvant compositions and methods of use
AU2010204139A1 (en) 2009-01-12 2011-08-11 Novartis Ag Cna_B domain antigens in vaccines against gram positive bacteria
NZ595234A (en) 2009-03-24 2013-12-20 Novartis Ag Adjuvanting meningococcal factor h binding protein
CA2756533A1 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
PL2510947T3 (pl) 2009-04-14 2016-09-30 Kompozycje do immunizacji przeciwko Staphylococcus aureus
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
WO2010151544A1 (en) 2009-06-22 2010-12-29 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
JP2012530785A (ja) 2009-06-22 2012-12-06 ワイス・エルエルシー 組成物および黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）血清型５および８莢膜多糖コンジュゲート免疫原性組成物を調製するための方法
WO2011017101A2 (en) * 2009-07-27 2011-02-10 Fina Biosolutions, Llc Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
KR20130127547A (ko) 2009-07-30 2013-11-22 화이자 백신스 엘엘씨 항원성 타우 펩타이드 및 이의 용도
WO2011024072A2 (en) 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
ES2670576T3 (es) * 2009-09-03 2018-05-31 Pfizer Vaccines Llc Vacuna de PCSK9
CN102695523A (zh) 2009-09-10 2012-09-26 诺华有限公司 针对呼吸道疾病的组合疫苗
BR112012010531A2 (pt) 2009-10-27 2019-09-24 Novartis Ag "polipeptídeos de modificação meningocócica fhbp"
JP5914344B2 (ja) 2009-10-30 2016-05-11 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ５型および８型の莢膜糖の精製
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011084705A2 (en) 2009-12-17 2011-07-14 Fina Biosolutions, Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
SG10201408505SA (en) 2009-12-22 2015-02-27 Celldex Therapeutics Inc Vaccine compositions
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
ES2910199T3 (es) 2010-03-30 2022-05-11 Childrens Hospital & Res Center At Oakland Proteínas de unión al factor H (fHbp) con propiedades alteradas y métodos de uso de las mismas
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
JP2013530949A (ja) * 2010-05-20 2013-08-01 エル ラウンド ジューン 抗原特異的Ｔｒｅｇ並びに関連する組成物、方法及びシステム
PL3170508T3 (pl) * 2010-06-04 2020-04-30 Wyeth Llc Preparaty szczepionek
EP2942061A3 (en) 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige ch3 peptide vaccine
WO2011154863A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
EP2655389A2 (en) 2010-12-24 2013-10-30 Novartis AG Compounds
EP2667852B1 (en) 2011-01-27 2016-11-09 GlaxoSmithKline Biologicals SA Adjuvant nanoemulsions with crystallisation inhibitors
EP2680885B8 (en) 2011-03-02 2018-07-25 GlaxoSmithKline Biologicals SA Combination vaccines with lower doses of antigen and/or adjuvant
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
WO2012129483A1 (en) 2011-03-24 2012-09-27 Novartis Ag Adjuvant nanoemulsions with phospholipids
EP2511295A1 (en) 2011-04-15 2012-10-17 Institut National De La Sante Et De La Recherche Medicale Compositions for preventing and/or treating an infection by an HIV-1 virus
US20130203980A1 (en) 2011-05-06 2013-08-08 Petr Gennadievich Aparin Exopolysaccharide of shigella sonnei bacteria, method for producing same, vaccine and pharmaceutical composition containing same
BR112013032410A2 (pt) 2011-06-24 2017-01-17 Epitogenesis Inc composições farmacêuticas compreendendo uma combinação de veículos, vitaminas, taninos e flavonoides de seleção como imunomoduladores específicos de antígeno
WO2013009564A1 (en) 2011-07-08 2013-01-17 Novartis Ag Tyrosine ligation process
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
WO2013038375A2 (en) 2011-09-14 2013-03-21 Novartis Ag Methods for making saccharide-protein glycoconjugates
US20140235667A1 (en) 2011-09-22 2014-08-21 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
AU2012335208B2 (en) 2011-11-07 2017-08-31 Glaxosmithkline Biologicals S.A. Carrier molecule comprising a spr0096 and a spr2021 antigen
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
SG11201402375VA (en) 2011-12-08 2014-10-30 Novartis Ag Clostridium difficile toxin-based vaccine
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
US10596246B2 (en) 2011-12-29 2020-03-24 Glaxosmithkline Biological Sa Adjuvanted combinations of meningococcal factor H binding proteins
AU2013224026A1 (en) 2012-02-24 2014-08-21 Novartis Ag Pilus proteins and compositions
JP2015510872A (ja) 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
CN104159603A (zh) 2012-03-08 2014-11-19 诺华股份有限公司 带有tlr4激动剂的联合疫苗
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
RU2727476C2 (ru) 2012-04-26 2020-07-21 Новартис Аг Антигены и антигенные композиции
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
SG11201406592QA (en) 2012-05-04 2014-11-27 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
JP2015518845A (ja) 2012-05-22 2015-07-06 ノバルティス アーゲー 髄膜炎菌血清群ｘコンジュゲート
RU2015106930A (ru) 2012-09-06 2016-10-20 Новартис Аг Комбинированные вакцины с менингококком серогруппы в и к/д/с
US9855324B2 (en) 2012-10-03 2018-01-02 Glaxosmithkline Biologicals Sa Immunogenic compositions
BR112015008040A2 (pt) 2012-10-12 2017-07-04 Glaxosmithkline Biologicals Sa composição de vacina, vacina de combinação, e, processos para preparar um componente ap e para a fabricação de uma composição de vacina
KR20150072444A (ko) * 2012-10-17 2015-06-29 글락소스미스클라인 바이오로지칼즈 에스.에이. 하나 이상의 스트렙토코커스 뉴모니애 캡슐 사카라이드 컨쥬게이트 및 해모필루스 인플루엔자로부터의 단백질 Ｅ 및／또는 ＰｉｌＡ를 포함하는 단백질 성분을 포함하는 면역원성 조성물
KR20140075201A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
CN105188747A (zh) 2013-02-01 2015-12-23 葛兰素史密斯克莱生物公司 包含toll样受体激动剂的免疫组合物的皮内递送
CN112999344A (zh) 2013-05-15 2021-06-22 阿尔伯达大学董事会 E1e2 hcv疫苗及使用方法
CN103386126B (zh) * 2013-06-25 2015-06-17 北京科兴生物制品有限公司 一种含肠道病毒抗原的多价免疫原性组合物
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PL3096785T3 (pl) 2014-01-21 2021-03-08 Pfizer Inc. Kompozycje immunogenne zawierające skoniugowane antygeny sacharydów otoczkowych i ich zastosowania
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
BR112016019735A2 (pt) 2014-02-28 2017-10-17 Glaxosmithkline Biologicals Sa fhbp, polipeptídeo, plasmídeo ou outro ácido nucleico, célula hospedeira, vesículas de membrana, e, composição imunogênica
EP2921856B1 (en) * 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
CN104829711B (zh) * 2014-04-08 2018-04-03 北京天成新脉生物技术有限公司 脑膜炎球菌荚膜多糖单克隆抗体及其应用
WO2016014719A1 (en) 2014-07-23 2016-01-28 Children's Hospital & Research Center Oakland Factor h binding protein variants and methods of use thereof
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
EP3244917B1 (en) 2015-01-15 2023-04-19 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CN104548090B (zh) * 2015-01-27 2016-11-30 中国科学院过程工程研究所 一种β-葡聚糖修饰的脑膜炎多糖结合疫苗及其制备方法
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
EP3109255A1 (en) 2015-06-26 2016-12-28 Institut National De La Recherche Agronomique Immunogenic composition
JP2018522885A (ja) 2015-07-07 2018-08-16 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ ＩｇＥ介在性疾患の処置および予防のためのワクチン
MY192183A (en) 2015-07-21 2022-08-05 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
JP6884145B2 (ja) 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
MX2018006785A (es) 2015-12-04 2018-11-09 Dana Farber Cancer Inst Inc Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer.
ES2811523T3 (es) 2016-01-19 2021-03-12 Pfizer Vacunas contra el cáncer
EP3439704A1 (en) 2016-04-05 2019-02-13 GSK Vaccines S.r.l. Immunogenic compositions
SG11201900794PA (en) 2016-08-05 2019-02-27 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2017306708B2 (en) 2016-08-05 2021-08-26 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
JP7104027B2 (ja) 2016-09-02 2022-07-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 淋菌に対するワクチン
EP3522916A2 (en) 2016-10-07 2019-08-14 Enterome S.A. Immunogenic compounds for cancer therapy
EP3522915A2 (en) 2016-10-07 2019-08-14 Enterome S.A. Immunogenic compounds for cancer therapy
US20210108002A1 (en) 2016-12-06 2021-04-15 Glaxosmithkline Biologicals Sa Purification Process For Capsular Polysaccharide
CN110198735A (zh) 2017-01-20 2019-09-03 辉瑞公司 用于肺炎球菌疫苗中的免疫原性组合物
CN110234658B (zh) 2017-01-31 2024-03-12 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
CN110662557A (zh) 2017-03-31 2020-01-07 葛兰素史克知识产权开发有限公司 免疫原性组合物、用途和治疗方法
EP3641808A1 (en) 2017-08-14 2020-04-29 GlaxoSmithKline Biologicals S.A. Methods of boosting immune responses
AU2019215216A1 (en) 2018-02-05 2020-07-23 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
MX2020007939A (es) 2018-02-05 2020-09-03 Sanofi Pasteur Inc Composicion del conjugado proteina-polisacarido multivalente nuemococica.
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
US20210106652A1 (en) 2018-04-11 2021-04-15 Enterome S.A. Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation
EP3773689B1 (en) 2018-04-11 2022-11-09 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
BR112020021296A2 (pt) 2018-04-18 2021-01-26 Sk Bioscience Co., Ltd. polissacarídeo capsular de streptococcus pneumoniae e conjugado imunogênico do mesmo
JP7446279B2 (ja) 2018-07-19 2024-03-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 乾燥多糖を調製するための方法
WO2020030572A1 (en) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP2022512345A (ja) 2018-12-12 2022-02-03 ファイザー・インク 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用
JP2022513458A (ja) 2018-12-12 2022-02-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｏ－結合型グリコシル化のための修飾キャリアタンパク質
WO2020165711A1 (en) 2019-02-11 2020-08-20 Pfizer Inc. Neisseria meningitidiscompositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US20220221455A1 (en) 2019-04-18 2022-07-14 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
CA3139257A1 (en) 2019-05-10 2020-11-19 Glaxosmithkline Biologicals Sa Conjugate production
US20230248816A9 (en) 2019-08-05 2023-08-10 Glaxosmithkline Biologicals Sa Process for preparing a composition comprising a protein d polypeptide
EP4010014A1 (en) 2019-08-05 2022-06-15 GlaxoSmithKline Biologicals S.A. Immunogenic composition
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
BR112022007203A2 (pt) 2019-10-16 2022-07-05 Enterome S A Compostos imunogênicos para tratamento de câncer adrenal
KR20220092572A (ko) 2019-11-01 2022-07-01 화이자 인코포레이티드 에스케리키아 콜라이 조성물 및 그 방법
BR112022009100A2 (pt) 2019-11-15 2022-07-26 Enterome S A Peptídeos antigênicos para prevenção e tratamento de malignidade de células b
CA3161857A1 (en) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
WO2021138495A1 (en) * 2019-12-30 2021-07-08 Fraunhofer Usa, Inc. Particles for multi-dose delivery
CA3171864A1 (en) 2020-02-21 2021-08-26 Pfizer Inc. Purification of saccharides
CN115605498A (zh) 2020-02-23 2023-01-13 辉瑞公司（Us） 大肠杆菌组合物及其方法
CN111588847B (zh) * 2020-05-18 2023-05-26 广州中医药大学(广州中医药研究院) 一种含有单磷酸化的脂质a与糖抗原的缀合物及其制备方法和应用
US20230250142A1 (en) 2020-06-12 2023-08-10 Glaxosmithkline Biologicals Sa Dock tag system
MX2023004912A (es) 2020-10-27 2023-05-16 Pfizer Composiciones de escherichia coli y metodos de las mismas.
KR20230097160A (ko) 2020-11-04 2023-06-30 화이자 인코포레이티드 폐렴구균 백신에 사용하기 위한 면역원성 조성물
WO2022101745A2 (en) 2020-11-10 2022-05-19 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
IL305313A (en) 2021-02-19 2023-10-01 Sanofi Pasteur Recombinant meningococcal B vaccine
EP4294433A1 (en) 2021-02-22 2023-12-27 GlaxoSmithKline Biologicals SA Immunogenic composition, use and methods
EP4070814A1 (en) 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
TW202306969A (zh) 2021-05-28 2023-02-16 美商輝瑞大藥廠 包含結合之莢膜醣抗原的免疫原組合物及其用途
BR112023023671A2 (pt) 2021-05-28 2024-02-06 Pfizer Composições imunogênicas compreendendo antígenos de sacarídeo capsular conjugados e usos dos mesmos
CA3237496A1 (en) 2021-11-18 2023-05-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20230116601A (ko) 2022-01-28 2023-08-04 이동민 머신 좌표계와 영상 좌표계의 정합 방법 및 장치
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023187127A1 (en) 2022-03-31 2023-10-05 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
WO2024110839A2 (en) 2022-11-22 2024-05-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US6841160B2 (en) * 1998-02-12 2005-01-11 Wyeth Holdings Corporation Meningococcal vaccines formulated with interleukin-12

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JP3237842B2 (ja) * 1988-12-16 2001-12-10 オランダ国 ニューモリシンミュータント及びそれから製造されたニューモコッカルワクチン
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
ATE188613T1 (de) 1992-06-25 2000-01-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
DE69331437T2 (de) * 1992-09-16 2002-09-05 Univ Tennessee Res Corp Antigene des hybriden m-proteins und träger für gruppe a streptokokkenimpfstoff
HU219056B (hu) 1993-03-23 2001-02-28 Smithkline Beecham Biologicals Sa 3-O-Dezacilezett monofoszforil-lipid A-t tartalmazó vakcinakészítmény
EP1300156A3 (en) 1993-05-18 2003-05-07 The Ohio State University Research Foundation Otitis media vaccine
JP3828145B2 (ja) 1993-09-22 2006-10-04 ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
ATE420171T1 (de) 1994-07-15 2009-01-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
KR19990007858A (ko) * 1995-04-17 1999-01-25 존 더블유.로우 박테리아의 리포프로테인으로 폴리사카라이드에 대한 면역반응의 유도및 강화
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
BR9608612A (pt) 1995-06-07 1999-05-04 Smithkline Beecham Biolog Vacina compreendendo um conjugado de antígeno de polissacarídeo - proteína portadora e proteína portadora livre
JPH11507214A (ja) 1995-06-07 1999-06-29 バイオケム ヴァシーンズ インク． Ｈｓｐ７０ファミリーに属する連鎖球菌の熱ショック蛋白質メンバー
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
ATE323721T1 (de) 1996-05-01 2006-05-15 Univ Rockefeller Cholin-bindendes protein, welches als gegen pneumokokken gerichtetes vakzin verwendet wird
US6245335B1 (en) * 1996-05-01 2001-06-12 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
JPH102001A (ja) * 1996-06-15 1998-01-06 Okajima Kogyo Kk グレーチング
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
AU739129B2 (en) 1997-06-03 2001-10-04 Connaught Laboratories Limited Lactoferrin receptor genes of moraxella
KR100619350B1 (ko) 1997-07-21 2006-09-05 박스터 헬쓰케어 에스.에이. 변형 면역성 뉴멀리신 백신조성물
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US20050031638A1 (en) * 1997-12-24 2005-02-10 Smithkline Beecham Biologicals S.A. Vaccine
EP1067962B1 (en) 1998-04-07 2010-03-24 MedImmune, LLC Derivatives of pneumococcal choline binding proteins for vaccines
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
CN1263510C (zh) 1998-08-19 2006-07-12 巴克斯特健康护理股份有限公司 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用
JP4689044B2 (ja) * 1998-12-21 2011-05-25 メディミューン，インコーポレーテッド ワクチン用の肺炎連鎖球菌タンパク質と免疫原断片
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
CZ303653B6 (cs) * 1999-03-19 2013-01-30 Smithkline Beecham Biologicals S. A. Imunogenní prostredek
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CN201252175Y (zh) * 2008-08-04 2009-06-03 富士康(昆山)电脑接插件有限公司 线缆连接器组件

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US6841160B2 (en) * 1998-02-12 2005-01-11 Wyeth Holdings Corporation Meningococcal vaccines formulated with interleukin-12

Cited By (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070116714A1 (en) * 1995-06-07 2007-05-24 Smithkline Beecham Biologicals Sa Vaccine Comprising a Polysaccharide Antigen-Carrier Protein Conjugate and Free Carrier Protein
US20060147466A1 (en) * 2002-05-14 2006-07-06 Chiron Srl Mucosal combination vaccines for bacterial meningitis
US8926992B2 (en) 2002-05-14 2015-01-06 Novartis Ag Mucosal vaccines with chitosan adjuvant and meningococcal antigens
US20110159030A1 (en) * 2002-05-14 2011-06-30 O'hagan Derek Mucosal combination vaccines for bacterial meningitis
US20070207090A1 (en) * 2002-05-14 2007-09-06 Novartis Vaccines And Diagnostics, Inc. Mucosal meningococcal vaccines
US20110150923A1 (en) * 2002-05-14 2011-06-23 Giuseppe Del Giudice Mucosal meningococcal vaccines
US20060051378A1 (en) * 2002-05-14 2006-03-09 Guidice Giuseppe D Mucosal vaccines with chitosan adjuvant and meningococcal antigens
RU2595845C2 (ru) * 2003-10-02 2016-08-27 Новартис Вэксинес Энд Дайэгностикс С.Р.Л. Жидкие вакцины для множественных серогрупп менингококков
TWI511739B (zh) * 2005-04-08 2015-12-11 Wyeth Corp 多價肺炎球菌多醣-蛋白質共軛物組合物
US20070184071A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US9480736B2 (en) 2005-04-08 2016-11-01 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US11969474B2 (en) 2005-04-08 2024-04-30 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US9981045B2 (en) 2005-04-08 2018-05-29 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US9399060B2 (en) 2005-04-08 2016-07-26 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US8895024B2 (en) 2005-04-08 2014-11-25 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20100316666A1 (en) * 2005-04-08 2010-12-16 Wyeth Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition
US20110071279A1 (en) * 2005-04-08 2011-03-24 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US9981035B2 (en) 2005-04-08 2018-05-29 Wyeth Llc Process for preparing pneumococcal polysaccharide-protein conjugates
US20090130137A1 (en) * 2005-04-08 2009-05-21 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US20110201791A1 (en) * 2005-04-08 2011-08-18 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US10716848B2 (en) 2005-04-08 2020-07-21 Wyeth Llc Process for preparing pneumococcal polysaccharide-protein conjugates
US10780160B2 (en) 2005-04-08 2020-09-22 Wyeth Llc Process for preparing pneumococcal polysaccharide-protein conjugates
US20120237542A1 (en) * 2005-04-08 2012-09-20 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20060228380A1 (en) * 2005-04-08 2006-10-12 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US8603484B2 (en) 2005-04-08 2013-12-10 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US11191830B2 (en) 2005-04-08 2021-12-07 Wyeth Llc Process for preparing pneumococcal polysaccharide-protein conjugates
US8895724B2 (en) 2005-04-08 2014-11-25 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US8808708B2 (en) * 2005-04-08 2014-08-19 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US11400147B2 (en) 2005-12-22 2022-08-02 Glaxosmithkline Biologicals Sa Pneumococcal capsular saccharide conjugate vaccine
EA014107B1 (ru) * 2005-12-22 2010-10-29 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
US9884113B2 (en) 2005-12-22 2018-02-06 Glaxosmithkline Biologicals, Sa Pneumoccal polysacchride conjugate vaccine
CN101374548B (zh) * 2005-12-22 2013-05-01 葛兰素史密丝克莱恩生物有限公司 含有肺炎链球菌荚膜多糖缀合物的疫苗
EP2382986A3 (en) * 2005-12-22 2012-08-22 GlaxoSmithKline Biologicals s.a. Vaccine against streptococcus pneumoniae
US9107872B2 (en) 2005-12-22 2015-08-18 Glaxosmithkline Biologicals S.A. Pneumococcal polysaccharide conjugate vaccine
WO2007071710A3 (en) * 2005-12-22 2007-11-29 Glaxosmithkline Biolog Sa Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
EA014165B1 (ru) * 2005-12-22 2010-10-29 Глаксосмитклайн Байолоджикалс С.А. Пневмококковая полисахаридная конъюгатная вакцина
EP3017827A1 (en) * 2005-12-22 2016-05-11 GlaxoSmithKline Biologicals s.a. Pneumococcal polysaccharide conjugate vaccine
EP3470080A1 (en) * 2005-12-22 2019-04-17 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
US20100074922A1 (en) * 2005-12-22 2010-03-25 Ralph Leon Biemans Pneumococcal polysaccharide conjugate vaccine
US20090017059A1 (en) * 2005-12-22 2009-01-15 Glaxosmithkline Biologicals S.A. Vaccine Comprising Streptococcus Pneumoniae Capsular Polysaccharide Conjugates
US10646564B2 (en) 2005-12-22 2020-05-12 Glaxosmithkline Biologicals S.A. Vaccine
US10279033B2 (en) 2005-12-22 2019-05-07 Glaxosmithkline Biologicals Sa Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates
US20090017072A1 (en) * 2005-12-22 2009-01-15 Glaxosmithkline Biologicals S.A. Vaccine
US9669084B2 (en) 2006-05-08 2017-06-06 Wyeth Llc Pneumococcal dosing regimen
US10406220B2 (en) 2006-05-08 2019-09-10 Wyeth Llc Pneumococcal dosing regimen
US8808707B1 (en) * 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
US11167020B2 (en) 2006-05-08 2021-11-09 Wyeth Llc Pneumococcal dosing regimen
US20110206692A1 (en) * 2006-06-09 2011-08-25 Novartis Ag Conformers of bacterial adhesins
US9610339B2 (en) * 2007-06-26 2017-04-04 Glaxosmithkline Biologicals, S.A. Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates
US20100209450A1 (en) * 2007-06-26 2010-08-19 Ralph Leon Biemans Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
US9610340B2 (en) * 2007-06-26 2017-04-04 Glaxosmithkline Biologicals, S.A. Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates
US20100239604A1 (en) * 2007-06-26 2010-09-23 Glaxosmithkline Biologicals. S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
US11622973B2 (en) 2007-11-09 2023-04-11 California Institute Of Technology Immunomodulating compounds and related compositions and methods
US11419887B2 (en) 2010-04-07 2022-08-23 California Institute Of Technology Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
EP2865392B1 (en) 2012-06-20 2016-11-16 SK Chemicals Co., Ltd. Polyvalent pneumococcal polysaccharide-protein conjugate composition
US10058607B2 (en) 2012-06-20 2018-08-28 Sk Chemicals Co., Ltd. Polyvalent pneumococcal polysaccharide-protein conjugate composition
US10034949B2 (en) 2012-06-20 2018-07-31 Sk Chemicals Co., Ltd. Polyvalent pneumococcal polysaccharide-protein conjugate composition
WO2013191459A1 (ko) * 2012-06-20 2013-12-27 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
US9981029B2 (en) * 2012-12-11 2018-05-29 Sk Chemical Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
US10772918B2 (en) 2013-05-10 2020-09-15 California Institute Of Technology Probiotic prevention and treatment of colon cancer
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
WO2015095868A1 (en) * 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
US10105431B2 (en) * 2014-01-21 2018-10-23 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
US11426456B2 (en) 2014-01-21 2022-08-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
US10918708B2 (en) 2014-01-21 2021-02-16 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
US9714283B2 (en) 2014-10-28 2017-07-25 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US11780906B2 (en) 2014-10-28 2023-10-10 Adma Biomanufacturing, Llc Compositions and methods for the treatment of immunodeficiency
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US9969793B2 (en) 2014-10-28 2018-05-15 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US10683343B2 (en) 2014-10-28 2020-06-16 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US11339206B2 (en) 2014-10-28 2022-05-24 Adma Biomanufacturing, Llc Compositions and methods for the treatment of immunodeficiency
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
US20190240309A1 (en) * 2016-06-22 2019-08-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
US11191822B2 (en) * 2016-06-22 2021-12-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
WO2017220753A1 (en) 2016-06-22 2017-12-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
US11897943B2 (en) 2017-03-15 2024-02-13 Adma Biomanufacturing, Llc Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2018169303A1 (ko) * 2017-03-15 2018-09-20 주식회사 엘지화학 다가 폐렴구균 백신 조성물
US11084870B2 (en) 2017-03-15 2021-08-10 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
US11376323B2 (en) 2017-06-10 2022-07-05 Inventprise, Llc Mixtures of polysaccharide protein pegylated compounds
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
US10688170B2 (en) 2017-06-10 2020-06-23 Inventprise, Llc Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
US11850278B2 (en) 2017-12-06 2023-12-26 Merck Sharp & Dohme Llc Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
US11116828B2 (en) 2017-12-06 2021-09-14 Merck Sharp & Dohme Corp. Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
US11642406B2 (en) 2018-12-19 2023-05-09 Merck Sharp & Dohme Llc Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
US12016914B2 (en) 2018-12-19 2024-06-25 Merck Sharp & Dohme Llc Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof

Also Published As

Publication number Publication date
DE60032120T2 (de) 2007-09-20
CY1107561T1 (el) 2013-03-13
CZ20013378A3 (cs) 2002-03-13
SI1163000T1 (sl) 2008-06-30
HUP0200367A2 (en) 2002-05-29
AR022963A1 (es) 2002-09-04
BRPI0009163B1 (pt) 2019-04-09
CZ20013379A3 (cs) 2002-03-13
KR20020000785A (ko) 2002-01-05
CN1351503A (zh) 2002-05-29
US20100119544A1 (en) 2010-05-13
CN1391481A (zh) 2003-01-15
ES2339737T3 (es) 2010-05-25
IL145043A (en) 2007-06-17
NO330532B1 (no) 2011-05-09
CZ20013380A3 (cs) 2002-03-13
ES2275499T3 (es) 2007-06-16
NZ513841A (en) 2001-09-28
KR20020001785A (ko) 2002-01-09
TWI281403B (en) 2007-05-21
CZ303653B6 (cs) 2013-01-30
TR200102739T2 (tr) 2001-12-21
MXPA01009452A (es) 2002-08-06
AU750762B2 (en) 2002-07-25
EP1162999A2 (en) 2001-12-19
JP4846906B2 (ja) 2011-12-28
IL145044A0 (en) 2002-06-30
PL355180A1 (en) 2004-04-05
ES2300255T3 (es) 2008-06-16
EP1162998A2 (en) 2001-12-19
EP1776962A1 (en) 2007-04-25
HUS1500040I1 (hu) 2018-05-28
JP2002540074A (ja) 2002-11-26
IL145045A0 (en) 2002-06-30
EP1880735A3 (en) 2008-03-12
AU3430700A (en) 2000-10-09
AU750913B2 (en) 2002-08-01
BR0009163A (pt) 2001-12-26
CN1351501A (zh) 2002-05-29
WO2000056358A2 (en) 2000-09-28
NO20014322L (no) 2001-11-14
EP1163000B1 (en) 2008-02-27
CA2366152A1 (en) 2000-09-28
CN100339130C (zh) 2007-09-26
ATE387214T1 (de) 2008-03-15
BR0009166A (pt) 2001-12-26
US20050031646A1 (en) 2005-02-10
NZ513842A (en) 2004-05-28
MY125387A (en) 2006-07-31
HK1043728A1 (en) 2002-09-27
WO2000056360A2 (en) 2000-09-28
CN1191852C (zh) 2005-03-09
JP2011057713A (ja) 2011-03-24
AR022964A1 (es) 2002-09-04
IL145043A0 (en) 2002-06-30
HU229968B1 (hu) 2015-03-30
NL300415I1 (nl) 2009-12-01
NO2011014I2 (no) 2011-08-30
IL145044A (en) 2007-03-08
PL203917B1 (pl) 2009-11-30
BR0009154A (pt) 2001-12-26
TR200102735T2 (tr) 2002-04-22
AR022965A1 (es) 2002-09-04
MY125202A (en) 2006-07-31
NZ513840A (en) 2004-02-27
AU3291900A (en) 2000-10-09
CN1192798C (zh) 2005-03-16
NO20014325L (no) 2001-11-14
ATE459373T1 (de) 2010-03-15
DE60038166D1 (de) 2008-04-10
US20110217329A1 (en) 2011-09-08
KR100798212B1 (ko) 2008-01-24
EP1880735A2 (en) 2008-01-23
NO20014322D0 (no) 2001-09-05
EP1162998B1 (en) 2010-03-03
US20060093626A1 (en) 2006-05-04
CY2009014I1 (el) 2010-07-28
NO20014323D0 (no) 2001-09-05
TR200102736T2 (tr) 2002-04-22
HUP0200373A2 (en) 2002-06-29
HK1043728B (zh) 2007-06-22
EP2277535A3 (en) 2011-03-09
US8926985B2 (en) 2015-01-06
EP2277535A2 (en) 2011-01-26
PT1162999E (pt) 2007-02-28
WO2000056359A3 (en) 2001-02-01
NO330736B1 (no) 2011-06-27
PL204890B1 (pl) 2010-02-26
NO20014323L (no) 2001-11-14
US20150079125A1 (en) 2015-03-19
NL300415I2 (uk) 2016-12-13
CA2365296A1 (en) 2000-09-28
PL355264A1 (en) 2004-04-05
TWI235064B (en) 2005-07-01
WO2000056360A3 (en) 2001-01-25
DK1162999T3 (da) 2007-03-26
CY1107390T1 (el) 2010-07-28
US9168313B2 (en) 2015-10-27
NO2011014I1 (no) 2011-09-19
JP2002539273A (ja) 2002-11-19
DE60032120D1 (de) 2007-01-11
NO20014325D0 (no) 2001-09-05
HK1043731B (zh) 2009-01-23
CA2366314C (en) 2012-01-10
DE60043930D1 (de) 2010-04-15
ATE346608T1 (de) 2006-12-15
FR10C0008I1 (fr) 2010-03-26
SI1162999T1 (sl) 2007-04-30
BRPI0009163B8 (pt) 2021-05-25
DE122009000054I1 (de) 2009-12-31
DK1163000T3 (da) 2008-04-28
WO2000056359A2 (en) 2000-09-28
BE1025464I2 (uk) 2019-03-06
AU750788B2 (en) 2002-07-25
EP1162999B1 (en) 2006-11-29
KR100642044B1 (ko) 2006-11-10
FR10C0008I2 (fr) 2012-10-26
TWI286938B (en) 2007-09-21
EP1163000A2 (en) 2001-12-19
WO2000056358A3 (en) 2001-01-04
CZ301445B6 (cs) 2010-03-03
PT1163000E (pt) 2008-03-20
US20100291138A1 (en) 2010-11-18
JP5551579B2 (ja) 2014-07-16
CA2366314A1 (en) 2000-09-28
HK1043731A1 (en) 2002-09-27
AU3813600A (en) 2000-10-09
KR20020000549A (ko) 2002-01-05
PL355178A1 (en) 2004-04-05
LU91652I9 (uk) 2019-01-03
DE60038166T2 (de) 2009-03-12
LU91652I2 (fr) 2010-10-13
HU228499B1 (en) 2013-03-28
CY2009014I2 (el) 2010-07-28
HUP0200664A2 (en) 2002-06-29
JP2002540075A (ja) 2002-11-26
US20060002961A1 (en) 2006-01-05
HK1043730A1 (zh) 2002-09-27

Similar Documents

Publication Publication Date Title
US9168313B2 (en) Vaccine
ZA200107638B (en) Vaccine.
US20150079129A1 (en) Vaccine
MXPA01009455A (en) Vaccine
MXPA01009459A (es) Vacuna

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION